

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER YAYON 4
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/831305
INTERNATIONAL APPLICATION NO. PCT/IL99/00602	INTERNATIONAL FILING DATE 08 November 1999	PRIORITY CLAIMED 08 November 1998
TITLE OF INVENTION PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES		
APPLICANT(S) FOR DO/EO/US Avner YAYON et al.		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31). <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been communicated by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been communicated by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <ol style="list-style-type: none"> <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: <ul style="list-style-type: none"> <input checked="" type="checkbox"/> Courtesy copy of the International Application as filed. <input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 00/27379). <input checked="" type="checkbox"/> Courtesy copy of the International Preliminary Examination Report. There were no annexes <input checked="" type="checkbox"/> Formal drawings, 16 sheets, Figures 1A-16. <input checked="" type="checkbox"/> Courtesy Copy of the International Search Report. 		



Form PTO-1390 (as slightly revised by Drouin and McIntyre)

09/831305

JG08 Rec'd PCT/PTO 08 MAY 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Art Unit:
Avner YAYON et al.)	
)	
IA No.: PCT/IL99/00602)	
)	Washington, D.C.
IA Filed: 08 November 1999)	
)	
U.S. App. No.:)	
(Not Yet Assigned))	
)	May 8, 2001
National Filing Date:)	
(Not Yet Received))	
)	
For: PHARMACEUTICAL...)	Docket No.: YAYON 4

PRELIMINARY AMENDMENT

Honorable Commissioner for Patents and Trademarks
Washington, D.C. 20231

Sir:

Contemporaneous with the filing of this case and
prior to calculation of the filing fee, kindly amend as
follows:

IN THE SPECIFICATION

After the title please insert the following
paragraph:

REFERENCE TO RELATED APPLICATIONS

The present application is the national stage under
35 U.S.C. 371 of international application PCT/IL99/00602,
filed 08 November 1999 which designated the United States, and
which international application was published under PCT
Article 21(2) in the English language.


In re of: Avner YAYON et al. (YAYON 4)

REMARKS

The above amendment to the specification is being made to insert reference to the PCT application of which the present case is a U.S. national stage.

Favorable consideration is earnestly solicited.

Respectfully submitted,
BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant

By: 
Jay M. Finkelstein
Registration No. 21,082

JMF:wrđ

Telephone No.: (202) 628-5197

Facsimile No.: (202) 737-3528

Rec'd PCT/PTO '18 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: YAYON=4

In re Application of:)	Art Unit:
)	
Avner YAYON et al)	
)	
IA No.: PCT/IL99/00602)	
)	Washington, D.C.
IA Filed: November 8, 1999)	
)	
U.S. Appln. No.: 09/831,305)	
)	
Deposited: May 8, 2001)	July 18, 2001
)	
For: PHARMACEUTICAL COMPOSITIONS)	
COMPRISING PORPHYRINS AND)	
SOME NOVEL PROPHYRIN)	
DERIVATIVES)	

SECOND PRELIMINARY AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination on the merits, please amend as follows:

IN THE CLAIMS

Please delete claims 1-57 and add new claims 58-89 as follows.

--58. A pharmaceutical composition for inhibiting growth factor receptor tyrosine kinase activity comprising a tetrapyrrolic macrocycle selected from the group consisting of 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole,

wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, and a pharmaceutically acceptable carrier.

--59. The pharmaceutical composition according to claim 58, wherein said growth factor receptor tyrosine kinase is selected from the group consisting of fibroblast growth factor (FGF) receptor tyrosine kinase, epidermal growth factor (EGF) receptor tyrosine kinase, heparin-binding EGF-like growth factor (HB-EGF) receptor tyrosine kinase, platelet derived growth factor (PDGF) receptor tyrosine kinase, vascular endothelial growth factor (VEGF) receptor tyrosine kinase, nerve growth factor (VGF) receptor tyrosine kinase, hepatocyte growth factor (HGF) receptor tyrosine kinase, insulin receptor tyrosine kinase and insulin-like growth factor (IGF) receptor tyrosine kinase.


--60. The pharmaceutical composition according to claim 59 for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity.

--61. The pharmaceutical composition according to claim 60 for: (i) inhibition of angiogenesis; (ii) inhibition of vascular smooth muscle cell proliferation in disorders including atherosclerosis, hypertrophic heart failure and postsurgical restenosis; (iii) inhibition of cell proliferation and migration in the treatment of primary tumors

and metastasis; (iv) treatment of nonmalignant tumors such as benign prostate hypertrophy; (v) treatment of diabetic retinopathy, psoriasis, rheumatoid arthritis, and other disorders including retrolental fibroplasia, macular degeneration, hemangioma, arteriovenous malformation, hypertrophic scars, acne, scleroderma and autoimmune diseases.

--62. The pharmaceutical composition according to claim 59 for the treatment of bone and cartilage related disorders including inherited skeletal disorders, e.g. achondroplasia, dwarfism, craniosynostosis.


--63. The pharmaceutical composition according to claim 58 wherein the 5,10,15,20-tetraaryl-porphyrin has the formula:



wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively

charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion.

--64. The pharmaceutical composition according to claim 58 wherein the 5,10,15,20-triaryl-corrole has the formula:



wherein Ar_1 , Ar_2 , and Ar_3 , the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

--65. The pharmaceutical composition according to claim 63, wherein said carboaryl radical by itself or as part of the mixed carboaryl-heteroaryl radical is a substituted monocyclic or bicyclic aromatic radical and said heteroaryl radical is a substituted 5-6 membered aromatic ring containing 1-3 heteroatoms selected from the group consisting of O, S and/or N.

--66. The pharmaceutical composition according to claim 65, wherein said carboaryl radical is selected from the group consisting of phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

--67. The pharmaceutical composition according to claim 66, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C₁-C₈) alkylammonium or amino-(C₁-C₈) alkylamino.

--68. The pharmaceutical composition according to claim 67, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-tetrafluorophenyl.

--69. The pharmaceutical composition according to claim 67, wherein one to four of said carboaryl radicals is 4-trimethylammonio-phenyl or 4-trimethylammonio-2,3,5,6-tetrafluorophenyl.

--70. The pharmaceutical composition according to claim 65, wherein said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from the group consisting of furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, triazinyl substituted by one or more halogen atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈

alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

--71. The pharmaceutical composition according to claim 70, wherein said one to four of said heteroaryl radicals is N-(C₁-C₈ alkyl)-pyridylum.

--72. The pharmaceutical composition according to claim 71, wherein said radical is selected from the group consisting of 2-, 3- or 4-(N-methyl) pyridylum.

--73. The pharmaceutical composition according to claim 63, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylum)-2,3,5,6-tetrafluoro-phenyl.

--74. The pharmaceutical composition according to claim 58, wherein said porphyrin compound is selected from the group consisting of the compounds herein designated **P1**, **P5**, **P6**, **P7**, **P8**, **P9**, **P10**, **P15**, **P16**, **P17**, **P18**, **P19** and **P20**, namely:

P1 5,10,15,20-tetrakis(N-methyl-4-pyridylum)-
21H,23H-porphine tetra-p-tosylate

P5 5,10,15,20-tetrakis[4-(trimethylammonio)
phenyl]-21H,23H-porphine tetra-p-tosylate

P6 5,10,15,20-tetrakis (N-methyl-4-pyridylum)-
21H,23H-porphine aluminium hydroxide
tetraiodide

P7 5,10,15,20-tetrakis(N-methyl-2-pyridylum)-
21H,23H-porphine tetraiodide

- P8** 5,10,15,20-tetrakis(N-methyl-4-pyridylum)-
21H,23H-porphine tetraiodide
- P9** 5,10,15,20-tetrakis(N-methyl-2-pyridylum)-
21H,23H-porphine tetra-p-tosylate
- P10** 3,8,13,18-tetrakis(N-methyl-4-pyridylum)-
21H,23H-porphine tetraiodide
- P15** 5,10,15,20-tetrakis(2,3,5,6-tetrafluoro-4-
trimethylammonio-phenyl)-21H,23H-methyl-
porphine tetra-trifluoromethylsulfonate
- P16** 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-
pyridylum)-21H,23H-porphine triiodide
- P17** 5,15-bis(pentafluorophenyl)-10,20-bis(N-methyl-
4-pyridylum)-21H,23H-porphine diiodide
- P18** 5,10-bis(pentafluorophenyl)-15,20-bis(N-methyl-
4-pyridylum)-21H,23H-porphine diiodide
- P19** 5,10,15-tris(N-methyl-4-pyridylum)-20-
(2,3,5,6-tetrafluoro-4-aminopropyl-amino-
phenyl)-21H,23H-porphine triiodide
- P20** 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylum)
2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine
tetraiodide

--75. The pharmaceutical composition according to
claim 58 wherein said corrole compound is 5,10,15-
tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylum)]-
21H,23H-corrole triiodide, herein designated **P21**.


--76. The pharmaceutical composition according to claim 61 for inhibition of angiogenesis comprising the compound 5,10,15,20-tetrakis(N-methyl-4-pyridylium)-21H,23H-porphine tetra-p-tosylate or 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide.

--77. The pharmaceutical composition according to claim 61 for inhibition of vascular smooth muscle cell proliferation in postsurgical restenosis comprising the compound 5,10,15,20-tetrakis(N-methyl-4-pyridylium)-21H,23H-porphine tetra-p-tosylate or 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide.

--78. The pharmaceutical composition according to claim 61 for inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis comprising a compound selected from the group consisting of the compounds 5,10,15,20-tetrakis(N-methyl-4-pyridylium)-21H,23H-porphine tetra-p-tosylate; 5,10,15,20-tetrakis[4-(trimethylammonio) phenyl]-21H,23H-porphine tetra-p-tosylate; 5,10,15,20-tetrakis(N-methyl-2-pyridylium)-21H,23H-porphine tetraiodide; 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide; and 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide.

--79. The pharmaceutical composition according to claim 62 for inhibition of EGFR-3 tyrosine kinase activity and treatment of achondroplasia, comprising the compound 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylum)-21H,23H-porphine triiodide.

--80. A 5,10,15,20-tetraaryl-porphyrin of the formula:



wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, and wherein at least one of the non-positively charged aryl radicals, if present, is pentafluorophenyl or 4-amino(C_1 - C_8)alkylamino-2,3,5,6-tetrafluorophenyl, and at least two of the positively charged aryl radicals are N -(C_1 - C_8)alkyl-pyridylum or 4-(N - C_1 - C_8 alkyl-pyridylum)-2,3,5,6-tetrafluoro-phenyl.


--81. The porphyrin of claim 80 being selected from the group consisting of the compounds: 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylium)-21H,23H-porphine triiodide; 5,15-bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylium)-21H,23H-porphine diiodide; 5,10-bis(pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylium)-21H,23H-porphine diiodide; 5,10,15-tris(N-methyl-4-pyridylium)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-amino-phenyl)-21H,23H-porphine triiodide and 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide.

--82. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a tetrapyrrolic macrocycle selected from the group consisting of a 5,10,15,20-tetraaryl-porphyrin according to claim 80 and a 5,10,15-triaryl-corrole, wherein said aryl radical of the corrole compound is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged.

--83. A pharmaceutical composition according to claim 82 wherein said 5,10,15,20-tetraaryl-porphyrin is selected from the group consisting of the compounds: 5-pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylium)-21H,23H-porphine triiodide; 5,15-bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylium)-21H,23H-porphine diiodide; 5,10-bis(pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylium)-

21H,23H-porphine diiodide; 5,10,15-tris(N-methyl-4-pyridylium)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-amino-phenyl)-21H,23H-porphine triiodide and 5,10,15,20-tetrakis[4-(N-methyl-2-pyridylium) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide.

--84. A pharmaceutical composition according to claim 82 wherein the 5,10,15-triaryl-corrole has the formula:



wherein Ar_1 , Ar_2 , and Ar_3 , the same or different, are each an aryl radical selected from the group consisting of a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

--85. The pharmaceutical composition according to claim 84 wherein the 5,10,15-triaryl-corrole is the compound herein designated 5,10,15-tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylium)]-21H,23H-corrole triiodide.

--86. A method for inhibiting growth factor receptor tyrosine kinase activity comprising the administration of an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit growth factor receptor activity.

--87. A method for inhibiting angiogenesis comprising the administration of an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit angiogenesis.

--88. A method for prevention of restenosis after percutaneous transluminal coronary angioplasty comprising the administration of an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit smooth muscle cell proliferation.

--89. A method for inhibiting primary tumor growth and metastasis comprising the administration of an inhibitor which is a tetrapyrrolic macrocycle selected from the group consisting of 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit primary tumor growth and metastasis.--

In re of Appln. No. 09/831,305


REMARKS

Claims 58-89 presently appear in this case. The present amendment is being made to put the case into better condition for examination. Prompt consideration and allowance are hereby earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By



Roger L. Browdy
Registration No. 25,618

RLB:rd
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\,W\Webb\Yayon4\PTO\AmendmentB.doc

**PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS
AND SOME NOVEL PORPHYRIN DERIVATIVES**

FIELD OF THE INVENTION

5 The present invention relates to inhibition of growth factor tyrosine kinase receptor activity, particularly inhibition of angiogenesis and related disorders, tumor progression and growth factor-related skeletal disorders, by porphyrin and corrole compounds, and to certain novel porphyrin compounds.

10 **ABBREVIATIONS:** AP, alkaline phosphatase; EGF, epidermal growth factor; bFGF, basic fibroblast growth factor; FGF, fibroblast growth factor; FGFR, FGF receptor; FGFR-1, FGF receptor-1; FGFR-3, FGF receptor-3; FRAP, FGFR-1-alkaline phosphatase fusion protein; FR3-AP, FGFR-3-alkaline phosphatase fusion protein; HB-EGF, heparin-binding EGF-like growth factor; HGF, hepatocyte growth factor;
15 HSPG, heparan sulfate proteoglycans; IGF, insulin-like growth factor; LLC, Lewis Lung Carcinoma; NGF, nerve growth factor; PDGF, platelet-derived growth factor; SMC, smooth muscle cells; TKR, tyrosine kinase receptor; VEGF, vascular endothelial growth factor; VSMC, vascular smooth muscle cells.

20 **BACKGROUND OF THE INVENTION**

Growth factors play a pivotal role in the multistep pathway of cell differentiation and migration, tumor and metastasis progression, and angiogenesis.

The pathological mechanism of many proliferative diseases is determined by biological events such as growth factor receptor stimulation, autophosphorylation, and
25 the phosphorylation of intracellular protein substrates.

Phosphorylation of tyrosine residues on protein substrates in normal cells serves a critical function in intracellular growth signaling pathways initiated by stimulated extracellular growth factor receptors. Growth factors such as fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), nerve
30 growth factor (NGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), associate with their respective extracellular receptors thus activating the intracellular tyrosine kinase domains of said receptors and catalyzing the

phosphorylation of the receptors themselves (autophosphorylation) or of intracellular substrates. This association between the growth factor ligand and the respective receptor stimulates tyrosine kinase activity as one of the initial biochemical events leading to DNA synthesis and cell division. Therefore, compounds which inhibit protein tyrosine
5 kinases associated with intracellular growth factor signal transduction pathways may be useful for the treatment of cellular proliferative disorders.

Fibroblast growth factors (FGFs) are abundant in normal and malignantly transformed cells and play a pivotal role in the multistep pathway of malignant transformation, tumor progression, metastasis and angiogenesis. In adults, bFGF, as
10 well as the FGF oncogenes HST (FGF-4) and int-2 (FGF-3) are found in tumors such as stomach cancer, Kaposi's sarcoma, melanoma and breast cancer.

FGFs bind avidly to the glycosaminoglycan heparin and to heparan sulfate proteoglycans (HSPG) found on cells and in the extracellular matrix. Studies on the mode of action of FGFs identified a novel role for heparin-like molecules in the
15 formation of distinct FGF-heparin complexes that are essential for binding of FGF to its cognate receptor (Yayon et al, 1991; Rapraeger et al, 1991). We and others have recently addressed the importance of specific heparin and heparan sulfate structures in FGF receptor binding activity (Guimond et al, 1993; Aviezer et al, 1994a) and have demonstrated that specific HSPGs such as perlecan, function as a low affinity, accessory
20 receptor for bFGF and as a potent angiogenic modulator (Aviezer et al, 1994b).

FGF receptors were found to play a role in genetically acquired growth disorders. Thus, a number of mutations in FGF receptors have been implicated in various forms of human skeletal dysplasias. For instance, achondroplasia, the most common form of human dwarfism, is caused by a specific mutation in the
25 transmembrane domain of FGFR-3 (Rousseau et al, 1994 ; Shiang et al, 1994). Other skeletal disorders such as Crouzon's syndrome and thanatophoric dysplasia, involve mutations in the extracellular domain (Reardon et al, 1994) or the kinase domain of FGF receptors. In achondroplasia, a point mutation (Gly380/Arg) in the transmembrane domain of FGFR-3 leads to impaired growth. Since we have identified FGF-9 as a
30 putative ligand for FGFR-3 (Hecht et al, 1995), it is conceivable that strategies aimed at check points along the biochemical mechanism of the FGFR-3 activation pathway, may result in treatment of achondroplasia. Naski et al, 1996, have demonstrated that both the

achondroplasia and thanatophoric dysplasia mutations constitutively activate the receptor as evidenced by receptor tyrosine phosphorylation. These findings have been biologically supported by knock out of the FGFR-3 gene (Deng et al, 1996). Furthermore, it seems that FGFRs are involved in bone and cartilage benign tumors, such as hereditary multiple exostosis, osteoarthritis and others. Exostosis is an osteocartilaginous benign tumor of an autosomal dominance, diversified phenotype and heterogeneous genetics characterized by the formation of cartilaginous capped metaphyseal bony protrusions.

Vascular endothelial growth factor (VEGF) is a known endothelial mitogen and a potent enhancer of vascular permeability. VEGF is a multifunctional cytokine that exerts *in vivo* a key role in physiological and pathological neoangiogenesis by stimulating endothelial cell proliferation and vessel hyperpermeability. VEGF exists as one of four different isoforms, respectively, VEGF 121, VEGF 165, VEGF 189, and VEGF 206. VEGF121 does not bind heparin while the other three isoforms do, and it has been documented that the binding of VEGF165 to its receptor is dependent upon cell surface heparin sulfate proteoglycans (Gitay-Goren et al, 1992). VEGF binds to Flt-1 and Flk-1/KDR cell membrane receptors which are members of the tyrosine kinase receptor family. VEGF seems to be a crucial mediator of physiological neoangiogenesis during the embryonic development and the female cycle.

VEGF also has a major role in the pathogenesis of many diseases including hypervascularized tumors, rheumatoid arthritis, cutaneous diseases and proliferative retinopathies. VEGF gene expression *in vitro* is enhanced approximately ten times by hypoxia. Current evidence (Patt et al, 1998) suggests that hypoxia is also the driving force for VEGF gene expression in cells *in vivo* and represents the most important trigger for tumor angiogenesis and edema. Recent approaches to inhibit tumor angiogenesis and metastasis formation concentrate on the disruption of VEGF/VEGF receptor signal transduction pathway *in vivo*. Persistent angiogenesis may cause or exacerbate certain diseases such as psoriasis, rheumatoid arthritis, hemangiomas, angiofibromas, diabetic retinopathy and neovascular glaucoma. An inhibitor of VEGF activity would be useful as a treatment for such diseases and other VEGF-induced pathological angiogenesis and vascular permeability conditions, such as tumor vascularization.

The EGF receptor, which main ligands are EGF, HB-EGF and transforming growth factor α (TGF- α), is involved in the disease processes of many malignant tumors, especially colon and breast cancers. Overexpression and mutation of the closely related Erb-2 and Erb-3 receptors have been shown to be the major risk factors in poor prognosis of breast cancer. HB-EGF is a most potent activator of the EGF receptor on smooth muscle cells (SMC), including VSMC, playing a crucial role in the pathogenesis of atherosclerosis and benign hypertrophy of the uterus and the formation of leiomyomas (tumors composed of nonstriated muscular tissue).

PDGF has been identified as a potent endogenous vascular smooth muscle cells (VSMC) mitogen and chemoattractant. Proliferation and directed migration of VSMC are important elements in processes such as vascular remodeling, atherosclerosis and restenosis. In balloon-injured rat model, elevated vascular mRNA expression of PDGF A and B chains and PDGF receptors has been observed in carotid arteries (J. Cell Biology, 1990, 111: 2149-2158) and infusion of PDGF greatly increased intimal thickening and migration of VSMC (J. Clin. Invest. 1992, 89: 507-511).

Hepatocyte growth factor (HGF), also known as scatter factor (SF), is the prototype of a family of structurally related soluble molecules (scatter factors), which also includes the HGF-like/macrophage-stimulating protein (HGF1/MSP). HGF and HGF1/MSP control a complex genetic program known as 'invasive growth' which leads to cell dissociation, proliferation, invasion of extracellular matrix, prevention of apoptosis, acquisition of polarity and tubule formation. HGF is synthesized by mesenchymal cells and is a paracrine effector of cells, predominantly epithelial, that express the Met tyrosine kinase receptor. The HGF and HGF1/MSP receptors are the tyrosine kinases encoded by the homologous genes *met* and *ron*. During development, coordinated control of invasive growth by HGF-Met is essential. Met and Ron receptor signalling occurs via a two-phosphotyrosine multifunctional docking site located in their C-terminal regions.

HGF is a pleiotropic cytokine known to be involved in tissue regeneration and repair (Van de Woude et al, 1997). HGF exerts mitogenic and motogenic effects in different cell types. One of the mechanisms by which HGF exerts its antiproliferative effect is induction of apoptosis. HGF activation of Ras and phosphatidylinositol-3-kinase through the multifunctional docking site is required for receptor-mediated

invasive growth. In a number of malignant tumours *met* and *ron* are mutated, amplified or overexpressed. Oncogenically activated *met* and *ron* confer transforming, invasive and metastatic properties to normal cells. Point mutations of the multifunctional docking site dissociate the transforming potential from the invasive-metastatic phenotype showing that distinct signalling pathways are involved. An increasing number of reports have implicated Met-HGF signalling in a variety of human cancers (Yanagawa et al, 1998).

Nerve growth factor (NGF) was characterized over 4 decades ago, and like the other neurotrophins subsequently discovered, it is best known for its trophic role, including the prevention of programmed cell death in specific populations of neurons in the peripheral nervous system. This property can be accounted for by the activation of a tyrosine kinase receptor. NGF also regulates neuronal function, as illustrated by its role in pain and inflammation, and in synaptic plasticity. Numerous studies published in the last 10-15 years have shown that NGF, a polypeptide originally discovered in connection with its neurotrophic activity, also acts on cells of the immune system. Finally, NGF recently was shown (Frade and Barde, 1998) to activate the neurotrophin receptor p75 (p75NTR), a receptor with no intrinsic catalytic activity and with similarities to members of the tumor necrosis factor receptor family. During normal development, the activation of p75NTR by NGF actually kills cells in the central nervous system (Frade and Barde, 1998). One remarkable property of NGF is then that it controls cell numbers in opposite ways in the developing nervous system, a result of its unique ability to activate two different receptor types. NGF has been found in various immune organs including the spleen, lymph nodes and thymus, and cells such as mast cells, eosinophils, and B and T cells (Aloe et al, 1997).

The circulating levels of NGF increase in inflammatory responses, in various autoimmune diseases, in parasitic infections, and in allergic diseases. Stress-related events both in animal models and in man also result in an increase of NGF, suggesting that this molecule is involved in neuroendocrine functions (Connor et al, 1998). The rapid release of NGF is part of an alerting signal in response to either psychologically stressful or anxiogenic conditions in response to homeostatic alteration. Thus, the inflammation and stress-induced increase in NGF might alone or in association with other biologic mediators induce the activation of immune cells during immunologic

insults. Recent evidence suggests that neurotrophic factors that promote the survival or differentiation of developing neurons may also protect mature neurons from neuronal atrophy in the degenerating human brain. Furthermore, it has been proposed that the pathogenesis of human neurodegenerative disorders may be due to an alteration in neurotrophic factor and/or trk receptor levels. The use of neurotrophic factors as therapeutic agents is a novel approach aimed at restoring and maintaining neuronal function in the central nervous system (CNS).

Porphyryns have been of interest of chemists and medical scientists for over a century. It has been known for many years that porphyryns interact with neoplastic tumors and the fact that porphyryns demonstrate high affinity to tumorigenic cells *in vitro* and solid tumors *in vivo*, is well established (Dougherty et al, 1998; Jori et al, 1986).

Porphyrin derivatives have been disclosed for the treatment of tumors, cancers and malignant tissues in combination with electromagnetic radiation or radioactive emissions. Since they absorb light strongly in the 690-880 nm region, many porphyryns were suggested for use as photosensitizers in photodynamic therapy (PDT). See, for example, US Patent Nos. 5,268,371 and 5,272,142, European Patent Nos. 213272 and 584552 and Jori et al. (1986).

Some porphyrin derivatives have been disclosed for use in combination with electromagnetic radiation or radioactive emissions for inhibiting angiogenesis. See, for example, the PCT publications WO 95/24930, WO 94/12239 and WO 93/02192 and US Patents Nos. 5,576,013 and 5,284,647. Some publications suggested the use of porphyrin derivatives as anti-tumor agents in the absence of electromagnetic radiation or radioactive emission based on their ability to cleave DNA (US 4,658,023 and US 5,236,914). The porphyryns disclosed in US Patent No. 5,236,914 always include a central Fe or Mn metal atom and may be substituted by 1 to 3 positively charged N-alkyl-pyridylium groups.

Corroles are slightly contracted porphyryns. The corroles are much less known than porphyryns and their synthesis is very complex. The first corrole was reported in 1965. A simple procedure for corrole synthesis is the subject of Israel Patent Application No. 126426. Neither this patent application nor any other publication disclose or suggest any pharmaceutical application of corroles.

None of the foregoing references teach or suggest that the porphyrin and corrole compounds of the compositions of the present invention inhibit growth factor receptor tyrosine kinase (RTK) activity.

5 **DESCRIPTION OF THE INVENTION**

It has now been found, according to the present invention, that certain porphyrin and corrole compounds can inhibit growth factor receptor tyrosine kinase (RTK) activity.

10 The present invention thus relates, in one aspect, to a pharmaceutical composition for inhibiting growth factor receptor tyrosine kinase (RTK) activity comprising a tetrapyrrolic macrocycle selected from a 5,10,15,20-tetraaryl-porphyrin and a 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, and a pharmaceutically acceptable carrier.

15 The growth factor RTK whose activity is inhibited by the compositions of the invention may be fibroblast growth factor (FGF) RTK, epidermal growth factor (EGF) RTK, heparin-binding EGF-like growth factor (HB-EGF) RTK, platelet-derived growth factor (PDGF) RTK, vascular endothelial growth factor (VEGF) RTK, nerve growth factor (VGF) RTK, hepatocyte growth factor (HGF) RTK, insulin RTK and insulin-like
20 growth factor (IGF) RTK.

All fibroblast growth factor receptors are encompassed by the invention but particularly FGFR-1 and FGFR-3 are envisaged, which ligands are, among others, bFGF and FGF9, respectively.

In one aspect, the pharmaceutical compositions of the invention are used for
25 inhibition of cell proliferation mediated by growth factor RTK activity. In one embodiment of this aspect, the compositions are used for inhibition of angiogenesis or neovascularization by particularly inhibiting the binding of VEGF to a VEGF receptor. The treatment of a condition characterized by excess of undesired angiogenesis with such a composition is not accompanied by any added electromagnetic radiation having a
30 frequency absorbed by the porphyrin or corrole derivative or any radioactive emissions from said derivatives. Preferred compounds according to the invention for treatment of

angiogenesis are the porphyrin herein designated **P1** and the corrole herein designated **P21**.

In another embodiment of this aspect, the compositions are used for inhibition of vascular smooth muscle cell proliferation in disorders including atherosclerosis, hypertrophic heart failure and postsurgical restenosis.


Restenosis after successful percutaneous transluminal coronar angioplasty (PTCA) remains a major problem despite great improvement in the technique, use of certain drugs and stents implantation. Heparin-binding growth factors (HBGF), mainly the FGFs and HB-EGF, play a crucial role in the pathogenesis of restenosis by enhancing medial smooth muscle cells (SMC) migration and proliferation and subsequently neo-intima formation. The FGF antagonists comprised in the compositions of the present invention interfere with the interaction between HBGF and their receptors and exert a marked inhibitory effect on SMC proliferation as shown by direct cell proliferation assays and reduced thymidine incorporation, as well as by direct inhibition of high affinity basic FGF *in vitro* and on cells. The inhibitors block ligand-receptor interaction by competitively inhibiting the essential association between both ligand and receptor with heparan sulfates and in a dose-dependent manner. According to the invention, porphyrin compounds **P1** and **P20** were found particularly active in the prevention of restenosis after PTCA by specifically inhibiting SMC proliferation and luminal narrowing by the neo-intima.

In another embodiment of this aspect, the compositions of the invention are used for inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis. The inhibition of tumor growth and metastasis, processes in which bFGF appears to play a pivotal role, was tested both *in vitro* and *in vivo* with the porphyrins and corroles. A clear inhibition of primary tumor formation in nude mice model and of primary tumor growth and metastasis in C57 black mice injected with LLC could be observed, particularly with the compounds herein designated **P1**, **P5**, **P7**, **P20** and **P21**.

In another embodiments of this aspect, the compositions of the invention are used for treatment of nonmalignant tumors such as benign prostate hypertrophy, diabetic retinopathy, psoriasis, rheumatoid arthritis, and other disorders including retrolental fibroplasia, macular degeneration, hemangioma, arteriovenous malformation, hypertrophic scars, acne, scleroderma and autoimmune diseases.


In another aspect, the pharmaceutical compositions of the invention are used for treatment of bone and cartilage related disorders including inherited skeletal disorders such as achondroplasia, dwarfism, craniosynostosis. According to the invention, the compounds, and particularly the porphyrin herein designated **P16**, were found to inhibit the binding of FGF9 to FGFR-3, indicating that they can be useful for treating FGFR-3 related growth disorders such as achondroplasia

The pharmaceutical composition of the invention comprises particularly a 5,10,15,20-tetraaryl-porphyrin of the formula:



wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, or

a 5,10,15-triaryl-corrole of the formula:



wherein Ar_1 , Ar_2 , and Ar_3 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

5 As defined herein, the carboaryl radical, by itself or as part of the mixed carboaryl-heteroaryl radical, is a substituted monocyclic or bicyclic aromatic radical and the heteroaryl radical, by itself or as part of the mixed carboaryl-heteroaryl radical, is a substituted 5-6 membered aromatic ring containing 1-3 heteroatoms selected from O, S and/or N.

10 The carboaryl radical may be phenyl, biphenyl or naphthyl substituted by one or more radicals including, but not being limited to, halogen, alkyl, alkoxy, alkylamino, aminoalkylamino, and trialkylammonium, wherein the alkyl radical may have from 1 to 8, preferably 1-4, carbon atoms. The halogen may be chloro or, preferably, fluor. The carboaryl radical may be a phenyl radical substituted by fluoro such as, for example,
15 pentafluorophenyl, or by tri(C_1 - C_8)alkylammonium, for example, 4-trimethylammoniophenyl, or it may have different substituents, for example, amino(C_1 - C_8)alkylamino-tetrafluorophenyl, e.g. 4-aminopropylamino-2,3,5,6-tetrafluorophenyl, or tri(C_1 - C_8)alkylammonium-tetrafluorophenyl, for example, 4-trimethylammoniophenyl-2,3,5,6-tetrafluorophenyl.


20 The heteroaryl radical may be a 5-6 membered aromatic ring containing 1-3 heteroatoms selected from O, S and/or N including, but not being limited to, furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl and triazinyl, substituted by one or more radicals including, but not being limited to, halogen, alkyl, alkoxy, alkylamino, aminoalkylamino, and trialkylammonium. Examples of such heteroaryl
25 radicals are N-(C_1 - C_8)alkyl-pyridylium, preferably 2-, 3- or 4-(N-methyl) pyridylium.

An example of a mixed carboaryl-heteroaryl radical according to the invention is N-(C_1 - C_8)alkyl-pyridylium-tetrafluorophenyl, for example, 4-(N-methyl-2-pyridylium)-2,3,5,6-tetrafluoro-phenyl and the corresponding 3- and 4-(N-methyl) pyridylium compounds.

30 The anion X^- according to the invention is a halide, preferably I^- , or a pseudo halide anion, or the anion of a carboxylic or sulfonic acid, for example from alkyl sulfonate, trifluoromethyl sulfonate or tosyl (p-toluene sulfonic acid).

Some of the porphyrins used in the present invention are known and either are commercially available or can be prepared by known procedures. **P1 – P5**, for example, are commercially available, and **P15**, for example, can be prepared according to La et al, 1997.


In another aspect, the invention relates to novel 5,10,15,20- tetraaryl -porphyrins of the formula:




wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, and wherein at least one of the non-positively charged aryl radicals, if present, is pentafluorophenyl or 4-amino(C_1 - C_8)alkylamino-2,3,5,6-tetrafluorophenyl, and at least two of the positively charged aryl radicals are N -(C_1 - C_8)alkyl-pyridylium or 4- N -(C_1 - C_8)alkyl-pyridylium-2,3,5,6-tetrafluorophenyl, particularly 4-(N -methyl-2-pyridylium)-2,3,5,6-tetrafluorophenyl, 4-(N -methyl-3-pyridylium)-2,3,5,6-tetrafluorophenyl or 4-(N -methyl-4-pyridylium)-2,3,5,6-tetrafluorophenyl.

The novel porphyrins of the invention include the compounds herein designated **P16, P17, P18, P19 and P20**, which formulas appear in **Appendix A**.

The novel porphyrins according to the invention corresponding to the general formula **II**:



10 in which Ar represents:



20 wherein the nitrogen atom (and the positive charge) is located at either the 2-, or 3-, or 4- position, and R represents C₁-C₈ linear or branched alkyl, and X⁻ represents a halide or pseudohalide anion, or the anion of a carboxylic or sulfonic acid, are prepared by a three-step method comprising:

a) condensation of pyrrole with a mixture of pentafluorobenzaldehyde and either 2-, or 3-, or 4-pyridinecarboxaldehyde in an acidic medium, such as to obtain a mixture of all possible substituted precursors in which the nitrogen atoms are tertiary and free of positive charges;

25 b) chromatographic separation of the above mentioned precursors by liquid chromatography. The relative amounts of each precursor are controlled in step (a), by adjusting the ratio of the appropriate pyridinecarboxaldehyde and pentafluorobenzaldehyde; and

30 c) each of the purified precursors obtained in step (b), after optional protection of the inner nitrogens of the porphyrin ring by magnesium or zinc, is subjected to an alkylation reaction by means of either an alkyl halide, or an alkyl tosylate, or an alkyl sulphate.

The corrole compounds used in the present invention are prepared by the method described in Gross *et al.*, 1999, which comprises solvent-free condensation of pyrrole with the appropriate aldehyde, followed by dehydrogenation and alkylation to obtain the desired salt.

5 In still another aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a tetrapyrrolic macrocycle selected from a novel 5,10,15,20-tetraaryl-porphyrin as defined above and a 5,10,15-triaryl-corrole, wherein said aryl radical of the corrole compound is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals
10 are positively charged. The novel porphyrins are preferably the compounds herein designated **P16**, **P17**, **P18**, **P19** and **P20**, and the corrole is preferably the compound **P21**.

In a further aspect, the invention relates to a method for inhibiting growth factor receptor tyrosine kinase (RTK) activity comprising the administration of an inhibitor
15 selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit growth factor receptor activity.

The invention further relates to a method for inhibiting angiogenesis comprising
20 the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit angiogenesis.

The invention still further relates to a method for prevention of restenosis after
25 percutaneous transluminal coronary angioplasty comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit smooth muscle
30 cell proliferation. For this purpose, the selected porphyrin or corrole may be used also in a slow release mode by direct administration into the affected site in the vessel wall or as a chemical conjugate with locally implanted stents.

The invention also relates to a method for inhibiting primary tumor growth and metastasis comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit primary tumor growth and metastasis.

The compositions of the present invention can be administered by any suitable mode of administration, e.g. orally or, preferably by injection, e.g. intravenously or subcutaneously, or by conjugation to locally implanted stents. The doses will depend on the condition of the patient and the disorder being treated and can be between 0.1 to 10 mg/kg/day, preferably from 1 to 5 mg/kg/day.

BRIEF DESCRIPTION OF THE DRAWINGS

Figs.1A-1C show inhibition of bFGF binding to the receptor FGFR-1 by the compound 5,10,15,20-tetrakis(N-methyl-4-pyridylium)-21H,23H-porphine tetra-p-tosylate, herein designated **P1** or **TMPP**, wherein:

Fig. 1A shows the inhibitory effect of **P1/TMPP** on soluble FGFR-1 alkaline phosphatase fusion protein (FRAP) binding to bFGF immobilized on heparin. The binding was carried out as described in Methods, section (ii). The alkaline phosphatase (AP) enzymatic activity measured at 405 nm represents the level of FRAP binding;

Fig. 1B shows the inhibitory effect of **P1/TMPP** on ¹²⁵I-bFGF binding to immobilized FRAP. The binding was carried out as described in Methods, section (iii). Results represent the mean value in one of at least two independent experiments; and

Fig. 1C shows the inhibitory effect of **P1/TMPP** on the binding of ¹²⁵I-bFGF to CHO cells transfected with FGFR-1. The binding was carried out as described in Methods, section (iv). Non-specific binding was determined in the presence of 100-fold excess of unlabeled bFGF ligand, and did not exceed 20% of the total bound ligand.

Fig. 2 shows the inhibitory effect of **P1** on the covalent cross-linking of ¹²⁵I-FGF and ¹²⁵I-FGF9 to CHO cells transfected with FGFR-1 and FGFR-3, respectively. Binding of ¹²⁵I-bFGF to confluent monolayers of FGFR-1 expressing CHO cells or ¹²⁵I-FGF9 to FGFR-3 expressing CHO cells, was performed as described in Methods, section (iv), in the presence or absence of **P1** (Inhibitor). After 90 min, disuccinylimidyl suberate [DSS]

(0.15 mM in PBS) was added and the protein complexes were separated by electrophoresis on a 7.5% SDS-polyacrylamide gel, and analyzed by autoradiography.

Fig. 3 illustrates an *in vitro* angiogenic assay using a rat aorta section immobilized in a collagen gel. Sections of rat aorta were immobilized in a collagen gel, and the extent of endothelial cell growth and microvascular tubules sprouting from the vessel tissue embedded in the gel was measured upon the addition of bFGF to the medium, in the absence (no inhibitor) or presence of 10 and 100 $\mu\text{g/ml}$ of P1. The results are expressed as the percent of microvascular tubule sprouting in comparison to the control experiment of bFGF addition. Basal tubule formation could be detected even when no additional factors were added.

Fig. 4 shows the inhibitory effect of P1 on tumor growth induced by signal peptide bFGF in a nude mice model. NIH 3T3 cells expressing signal peptide bFGF were injected subcutaneously to Balb/C nude mice. Twenty five $\mu\text{g/g}$ of body mass of free or liposome incorporated P1 were injected intraperitoneally (IP) twice a week. Tumor size was measured after 4 weeks.

Fig. 5 shows inhibition of primary tumor growth in the Lewis lung carcinoma (LLC) murine tumor model by porphyrin P1. Lewis lung carcinoma cells were injected into the foot pads of 10-week old C57 black mice. Twenty five $\mu\text{g/g}$ of body mass P1 were injected intraperitoneally twice a week and tumor size was measured after 4 weeks.

Fig. 6 shows inhibition of metastasis growth in the LLC murine tumor model by P1. Lewis lung carcinoma cells were injected into the foot pads of C57 black mice and primary tumors were allowed to develop. After their formation, the primary tumors were removed and metastases were allowed to develop for four weeks before mice were sacrificed. Twenty five $\mu\text{g/g}$ of body mass P1 were injected intraperitoneally twice a week. The mice were sacrificed, dissected and the lungs removed and photographed.

Fig. 7 depicts quantitative analysis of the inhibition of metastasis growth in the LLC murine tumor model by P1. Murine lung metastases were induced as described in Methods, section (vii). The mice were sacrificed and the extent of lung metastasis was measured by weighing the lungs.

Figs. 8A-8B show inhibition of bFGF binding to FGFR-1 wherein: Fig. 8A shows the effect of P7, P15-18 on soluble FGFR-1 alkaline phosphatase fusion protein (FRAP) binding to bFGF immobilized on heparin carried out, as described in Fig. 1A;

and Fig. 8B shows the effect of **P1**, **P20** and **P21** on ^{125}I -bFGF binding to immobilized FRAP, carried out as described in Fig. 1B.

Fig. 9 shows quantitative analysis of the inhibition of metastasis growth in the LLC tumor model by various porphyrins. The experiment was conducted as described in
5 Fig. 7.

Figs. 10A-10B show the effect of porphyrins on the binding of VEGF to its receptors, wherein:

Fig. 10A shows the effect of **P1** on the binding of ^{125}I -VEGF to endothelial cells transfected with the VEGF receptor KDR. Binding of ^{125}I -VEGF to confluent
10 monolayers of endothelial cells expressing KDR was performed as described in Methods, section (x), in the presence of increasing concentrations of **P1** and of unlabeled VEGF; and

Fig. 10B shows the effect of porphyrins **P1**, **P7**, **P15**, **P16** and **P18** on soluble VEGF receptor flt-1-AP fusion protein binding to VEGF immobilized to heparin,
15 carried out as described in Methods, section (ix).

Fig. 11 shows the inhibitory effect of porphyrins on binding of ^{125}I -FGF9 to immobilized FGFR-3. ^{125}I -FGF9 (2 ng/ml) was incubated (90 min, 4°C) with immobilized FGFR-3 as described in Methods, section (iii). Incubations were performed in the presence of 100 ng/ml heparin and increasing concentrations of porphyrins.
20 Non-specific binding was determined in the presence of 100-fold excess of unlabeled bFGF and did not exceed 10% of the total binding. Results represent the mean value in one of at least two independent experiments.

Fig. 12 shows the effect of porphyrins on the binding of ^{125}I -FGF9 to CHO cells transfected with FGFR-3. CHO mutant cells-745 expressing FGFR-3 were incubated for
25 90 min at 4°C in the presence of increasing concentrations of the porphyrins, with 1 µg/ml of heparin and ^{125}I -FGF9 (2 ng/ml). The binding medium was discarded and the cells were washed with ice cold DMEM/BSA. To determine receptor binding of ^{125}I -FGF9, the cells were incubated in cold PBS (pH 4) containing 1.6M NaCl and 25 mM HEPES, and the cell extract was counted in a γ-counter. Non-specific binding was
30 determined in the presence of 100-fold excess of unlabeled ligand, and did not exceed 20% of the total bound ligand.

Fig. 13 shows the effect of porphyrins **P1** and **P16** on FGF-9 induced mitogenic activity of FGFR-3 expressing cells. CHO cells genetically engineered to express FGFR-3 were grown in the presence of increasing concentrations of porphyrins **P1** and **P16** in order to determine the ability of the porphyrins to inhibit FGF-9 induced DNA synthesis.

Fig. 14 is an immunoblot showing total FGFR-3 tyrosine phosphorylation induced by FGF-9. Phosphorylation level of FGFR-3 tyrosine kinase in the presence of **P16** was demonstrated by immunoprecipitation of FGFR-3 with anti-FGFR-3 antibodies and immunoblotting with anti-phosphotyrosine antibodies.

Figs. 15 A-15B show PLC- γ and ERK phosphorylation of FGFR-3 expressing cells induced by FGF-9. Phosphorylation level of PLC- γ (Fig. 15A) and ERK (Fig. 15B) in the presence of FGF9 and **P16** was examined by immunoblotting with anti- PLC- γ or activated ERK antibodies.

Fig. 16 shows the inhibitory effect of **P1** on bFGF-induced mitogenic activity of smooth muscle cells.

DETAILED DESCRIPTION OF THE INVENTION

Fibroblast growth factors (FGF) and vascular endothelial growth factor (VEGF) play a pivotal role in the multistep pathway of malignant transformation, tumor progression, metastasis and angiogenesis. According to the present invention, 5,10,15,20-tetrakis (methyl-4-pyridyl)-21H,23H-porphine tetra-p-tosylate salt (**TMPP** or Compound **P1**), a member of the porphyrin molecule family, was identified as a potent inhibitor of basic FGF (FGF-2, bFGF) binding to FGF receptor and activation. **P1** demonstrated potent inhibition of binding of soluble FGF receptor 1 (FGFR-1) to bFGF immobilized on heparin at an IC₅₀ of 90 μ M. **P1** also inhibited direct binding of radiolabeled bFGF to FGFR in a cell free system as well as the binding to cells genetically engineered to express FGFR-1.

Furthermore, **P1** also inhibited the binding of VEGF to its tyrosine kinase receptor in a dose-dependent manner. In an *in vitro* angiogenic assay measuring the extent of endothelial cell growth and tube formation and sprouting, **P1** dramatically reduced the extent of the bFGF-induced endothelial cell outgrowth and differentiation, processes in which bFGF and VEGF play a pivotal role. In a Lewis lung carcinoma

model, mice having received P1 showed a marked inhibition of both primary tumor progression and lung metastases development, with nearly total inhibition of the metastatic phenotype upon alternate daily injections of P1 at 25 µg/g of body mass. Also in these processes bFGF and VEGF play a pivotal role.

5 In order to elucidate the structural requirements needed to achieve FGF and VEGF inhibitory activity, a series of porphyrin analogs was obtained or synthesized based on the structure of P1, and then examined.

The exact mechanism by which P1 and other related porphyrin-like molecules inhibit growth factor-receptor binding and activation is not clear. However, our results
10 suggest that P1 interferes with the formation of the tri-molecular complex of growth factor-heparin and the tyrosine kinase receptor (Yayon et al. 1991), thus abrogating receptor signaling. It is interesting to note that P1 does not inhibit the binding of EGF, which is not a heparin-binding or heparin-dependent growth factor (Aviezer and Yayon, 1994) to its high affinity tyrosine kinase receptor, suggesting that interfering with
15 heparin binding may play a key role in P1's inhibitory effect. Both the FGF ligand and the FGF receptor contain heparin-binding regions critical for FGF receptor activation (Schlessinger et al., 1995) and several inhibitors of FGF are direct competitors of heparin (Ornitz et al 1995, Miao et al 1997). P1 however does not resemble in its structure to any of the known heparin mimetics. Nevertheless the requirement for
20 positively charged groups and their spatial distribution may mimic a restricted highly sulfated domain in heparin thus serving as a heparin mimetic. Several other inhibitors of FGF and VEGF which have been shown to inhibit angiogenesis were designed to inhibit the intrinsic tyrosine kinase activity of the FGF and VEGF growth factor receptors (Mohammadi et al, 1997; Fong et al, 1999). This novel class of FGF and VEGF
25 inhibitors however, most likely works via a different molecular mechanism involving direct interference with growth factor receptor interaction, thus inhibiting their biological responses.

Porphyrin derivatives are widely used for the treatment of tumors and malignant tissues in combination with electromagnetic radiation or radioactive emissions. Since
30 they strongly absorb light in the 690-880 nm region, many porphyrins were suggested for use as photosensitizers in photodynamic therapy (PDT) (Jori et al, 1986). Some porphyrin derivatives are used in combination with electromagnetic radiation or

radioactive emissions for inhibiting angiogenesis (Margaron et al, 1996). It has been suggested that the activity of porphyrin derivatives as anti-tumor agents in the absence of electromagnetic radiation or radioactive emission may be based on their ability to cleave DNA since they must always include an excitable central Fe or Mn metal atom.

5 Here we find that porphyrin like compounds that do not contain a metal atom, can directly interfere with growth factor receptor tyrosine kinase interactions.

The potent antiproliferative effect of **P1** is of potential clinical application not only in the cancer field but also in other processes of pathological proliferation such as restenosis, accelerated atherosclerosis, and pathological angiogenesis as in diabetic

10 retinopathy and arthritis. In support is the observation that **P1** markedly inhibited the outgrowth of microvessels from aortic rings embedded in a collagen gel. Furthermore, **P1** and its analogs are potent inhibitors of vascular smooth muscle cell proliferation *in vitro*.

The fact that it was possible, according to the present invention, to improve the

15 potency of the **P1** lead compound for its FGF and VEGF inhibitory activity, by rationally modifying specific groups on the porphyrin backbone, is of great importance. Based on the structure of **P1** we have synthesized novel *meso* pyridylium substituted porphyrins, in which the position of the *N*-methyl (the positive charge) was varied from the *para*-position to *ortho* and *meta*, as well as porphyrins with less than four

20 4-pyridylium substituents. It was then found that only cationic charged porphyrins, but not neutral or anionic charged derivatives, were active.

When *meso*-pyridylium substituted porphyrins, as well as porphyrins with less than four 4-pyridylium substituents, were synthesized and tested, the most beneficial effect, as judged by the inhibition of bFGF binding, was obtained with 5,10,15-tris

25 (4-*N*-methylpyridylium)-20-(2,3,4,5,6-pentafluorophenyl) porphyrin triiodide (**P16**), a non symmetric porphyrin with three positive charges. The activity of **P16** *in vitro* was about 50 times higher than that of **P1**.

Another derivative, Compound **P20** (5, ,10,15,20-tetrakis[2,3,5,6-tetrafluoro-4-(*N*-methyl-2-pyridylium] porphyrin tetraiodide), which contains four positive charges at

30 more remote positions, was also significantly more active than **P1**. In the Lewis lung carcinoma tumor model however, only **P20**, but not **P16**, was more active than **P1**.

Finally, we have tested a novel water-soluble corrole analog of P1 (P21) (5,10,15-tris[2,3,5,6-tetrafluoro-4-(N-methyl-2-pyridylium)]corrole triiodide) (MW 1311.3), for its activity both for *in vitro* inhibition of bFGF binding and for the inhibition of tumor growth. Indeed, this novel derivative showing the advantages of having three positive charges as in P16, but with the same side groups as in P20, displayed the best of both P16 and P20 characteristics, and was found to be about 10 fold more active than P1 *in vitro* and 5 fold more potent in the *in vivo* tumor models, inhibiting lung metastasis formation *in vivo* at a concentration of only 5 mg/kg body weight. Furthermore, P21 synthesis takes a much more straight forward approach than P16 (Gross et al, 1999).

The novel *meso* pyridylium-substituted non symmetric porphyrins as well as the novel corrole-based derivatives of the invention demonstrated over 50 fold increase in activity *in vitro*, with significantly improved efficacy in blocking tumor progression and metastasis *in vivo*. The results with said novel rationally designed P1 porphyrin and corrole analogs demonstrate improved potency in inhibiting receptor binding, tumor progression and metastasis. Taken together, we have identified P1 and its analogs as a novel class of potent inhibitors of growth factors activity such as bFGF and VEGF activity *in vitro* and *in vivo*. These results suggest that rationally modified porphyrin and corrole analogs can serve as highly potent inhibitors of growth factor activity *in vitro* and *in vivo*.

The key to developing highly potent and specific anti tumor agents relies on the ability to perform chemical modifications along the course of the development process. The vast knowledge accumulated with regard to the biological and chemical properties of the porphyrins and corroles of the invention is therefore of great advantage for any potential medicinal chemistry approach. This fact, along with their capacity to block growth factor mediated tumor progression and angiogenesis, make these porphyrins and corroles highly attractive candidates for the development of anti-cancer and other drugs.

The invention will now be illustrated by the following non-limiting Examples.

30

EXAMPLES

For convenience of the presentation, this section of Examples will be divided into two sections: (I) Chemical Section, with a List of the Compounds, their synthesis

and characterization; and (II) Biological Section, with description of Materials, Methods and Biological Activity of the compounds.

I CHEMICAL SECTION – SYNTHESIS AND CHARACTERIZATION

5 LIST OF COMPOUNDS

In the Examples, the following compounds **P1-P21**, which formulas are presented in **Appendix A** hereinafter just before the References, will be identified by their symbols in bold:

- P1** 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine tetra-p-tosylate
- 10 **P2** 5,10,15,20-Tetrakis(pentafluorophenyl)-21H,23H-porphine
- P3** 5,10,15,20-Tetrakis(4-methoxyphenyl)-21H,23H-porphine
- P4** Tetrakis(4-cumyloxyphenoxy)phthalocyanine
- P5** 5,10,15,20-Tetrakis[4-(trimethylammonio)phenyl]-21H,23H-porphine
tetra-p-tosylate
- 15 **P6** 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine aluminium
hydroxide tetraiodide
- P7** 5,10,15,20-Tetrakis(N-methyl-2-pyridylum)-21H,23H-porphine tetraiodide
- P8** 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine tetraiodide
- P9** 5,10,15,20-Tetrakis(N-methyl-2-pyridylum)-21H,23H-porphine tetra-p-tosylate
- 20 **P10** 3,8,13,18-Tetrakis(N-methyl-4-pyridylum)- 21H,23H-porphine tetraiodide
- P11** 5,10,15,20-Tetrakis(4-carboxylatophenyl) 21H,23H-porphine tetraammonium
- P12** 5,10,15,20-Tetrakis(N-methyl-3-pyridylum)-21H,23H-porphine tetra-p-tosylate
- P13** 5,10,15,20-Tetrakis(N-methyl-3-pyridylum)-21H,23H-porphine tetraiodide
- 25 **P15** 5,10,15,20-Tetrakis(2,3,5,6-tetrafluoro-4-trimethylammonio-phenyl)-21H,
23H-methyl-porphine tetra-trifluoromethylsulfonate.
- P16** 5-Pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylum)-21H,23H-porphine
triiodide
- P17** 5,15-Bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylum)-21H,23H-
porphine diiodide
- 30 **P18** 5,10-Bis(pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylum)-21H,23H-
porphine diiodide
- P19** 5,10,15-Tris(N-methyl-4-pyridylum)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-

amino-phenyl)-21H,23H-porphine triiodide

P20 5,10,15,20-Tetrakis[4-(N-methyl-2-pyridylum) 2,3,5,6-tetrafluoro-phenyl]-
21H,23H-porphine tetraiodide

P21 5,10,15-Tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylum)]-21H,23H-
corrole triiodide

Compounds **P1-P13** and **P15** are known. Compounds **P1**, **P5-P10**, and **P15-P21** inhibit growth factor RTK activity in at least one of the assays tested and their use is encompassed by the present invention. Porphyrins **P16-P20** are new and are covered by the present invention. Corrole compound **P21** was first disclosed in Gross, 1999 and in Israel Patent Application No. 126426 filed on 29.09.1998 by one of the coapplicants of the present application but its pharmaceutical use is herein disclosed for the first time.

[I] Example 1.

Preparation of Compounds P16, P17, P18

1a) Preparation of the intermediate compounds – Condensation step

A mixture of 4.3 mL (45 mmol, 3 eq.) of 4-pyridinecarboxaldehyde, 2.06 mL (16.5 mmol, 1 eq.) of pentafluorobenzaldehyde, and 4.15 mL (60 mmol, 4 eq.) pyrrole was dissolved in 300 mL of acetic acid, and the mixture was heated to reflux for 2 h. After cooling to room temperature, the solvent was evaporated to dryness by vacuum and the oily residue was washed by hot water, neutralized by aqueous ammonia (25%), and washed again with hot water. The purple solids obtained by this procedure were filtered and dried. The dry solid material was treated with three portions of 50 mL of dichloromethane, each followed by filtration. To the combined organic phases, 10 g of silica were added, and the solvent was evaporated to dryness.

1b) Chromatographic separation

Separation and purification of the components obtained in step 1a was achieved by column chromatography, in which the polarity of the eluents was gradually increased from dichloromethane to mixtures of dichloromethane and 2-10% ethanol. The order of elution (the R_f values are for silica with 2% EtOH in CH_2Cl_2) and the chemical yields were as follows:

5,10,15,20-tetrakis(2,3,4,5,6-pentafluorophenyl)porphyrin (**1a**=**P2**, traces, $R_f = 0.95$).

5,10,15-tris(2,3,4,5,6-pentafluorophenyl)-20-(4-pyridyl)porphyrin (**1b**, 1.1%, $R_f = 0.66$).

5,15-bis(2,3,4,5,6-pentafluorophenyl)-10,20-bis(4-pyridyl)porphyrin (**1c**, $R_f = 0.60$)*.

5 5,10-bis(2,3,4,5,6-pentafluorophenyl)-15,20-bis(4-pyridyl)porphyrin (**1d**, $R_f = 0.54$)*.

5-(2,3,4,5,6-pentafluorophenyl)-10,15,20-tris(4-pyridyl)porphyrin (**1e**, 9.4%, $R_f = 0.45$).

5,10,15,20-tetrakis(4-pyridyl)porphyrin (**1f**, traces, $R_f = 0.18$).

* The combined yield of compounds **1c** and **1d** was 13.4%. Their separation required an additional column in which the eluent was 2% ethanol in dichloromethane.

10 Spectroscopic characteristics of the compounds (**1a** and **1f** are known compounds):

1a, UV-vis (CH_2Cl_2): λ_{max} (nm) 412, 506, 586; ^1H NMR (CDCl_3): δ 8.91 (s, 8H), -2.93 (s, 2H); ^{19}F NMR (CDCl_3): δ -136.9 (dd, $J_1 = 22.8$ Hz, $J_2 = 7.0$ Hz, 8F), -151.6 (t, $J = 20.7$ Hz, 4F), -161.7 (dd, $J_1 = 22.4$ Hz, $J_2 = 5.8$ Hz, 8F).

15 **1b**, UV-vis (CH_2Cl_2): λ_{max} (nm) 414, 506, 582; ^1H NMR (CDCl_3): δ 9.06 (d, $J = 4.3$ Hz, 2H), 8.89 (s, 6H), 8.16 (d, $J = 4.2$ Hz, 2H), 8.15 (s, 2H), -2.92 (s, 2H); ^{19}F NMR (CDCl_3): δ 137.0 (m, 6F), -151.8 (m (2 overlaying t), 3F), -161.8 (m, 6F); MS^+ (e/z) 886.1 (MH^+ , 100%), MS^- (e/z) 884.6 (M^- , 40%), ($[\text{M} - \text{H}]^-$, 60%).

20 **1c**, UV-vis (CH_2Cl_2): λ_{max} (nm) 412, 508, 584; ^1H NMR (CDCl_3): δ 9.06 (d, $J = 4.4$ Hz, 4H), 8.89 (s, 4H), 8.85 (s, 4H), 8.15 (d, $J_1 = 4.5$ Hz, 4H), -2.94 (s, 2H); ^{19}F NMR (CDCl_3): δ -137.2 (dd, $J_1 = 23.2$ Hz, $J_2 = 7.2$ Hz, 4F), -152.0 (t, $J = 20.9$ Hz, 2F), -161.9 ($J_1 = 22.8$ Hz, $J_2 = 7.3$ Hz, 4F); MS^+ (e/z) 797.4 (MH^+ , 100%), MS^- (e/z) 794.9 ($[\text{M} - \text{H}]^-$, 100%).

25 **1d**, UV-vis (CH_2Cl_2): λ_{max} (nm) 414, 508, 582; ^1H NMR (CDCl_3): δ 9.06 (d, $J = 5.8$ Hz, 4H), 8.89 (d, $J = 6.6$ Hz, 4H), 8.84 (m, 4H), 8.15 (dd, $J_1 = 4.3$ Hz, $J_2 = 1.5$ Hz, 4H), -2.90 (s, 2H); ^{19}F NMR (CDCl_3): δ -137.1 (dd, $J_1 = 23.4$ Hz, $J_2 = 8.1$ Hz, 4F), -152.0 (t, $J = 21.1$ Hz, 2F), -161.9 (td, $J_1 = 22.8$ Hz, $J_2 = 7.9$ Hz, 4F); MS^+ (e/z) 797.4 (MH^+ , 100%), MS^- (e/z) 794.9 ($[\text{M} - \text{H}]^-$, 100%).

1e, UV-vis (CH₂Cl₂): λ_{max} (nm) 416, 510, 586; ¹H NMR (CDCl₃): δ 9.05 (d, J = 5.4 Hz, 6H), 8.90 (d, J = 4.8 Hz, 2H), 8.84 (m (unresolved doublets), 6H), 8.14 (m (unresolved doublets), 6H), -2.92 (s, 2H); ¹⁹F NMR (CDCl₃): δ -137.3 (dd, J_1 = 22.8 Hz, J_2 = 7.9 Hz, 2F), -152.1 (t, J = 21.7 Hz, 1F), -162.0 (J_1 = 23.0 Hz, J_2 = 7.7 Hz, 2F);

5 MS⁺ (e/z) 708.1 (MH⁺, 100%), MS⁻ (e/z) 706.1 ([M - H]⁻, 100%).

1f, ¹H NMR (CDCl₃): δ 9.04 (d, J = 5.5 Hz, 8H), 8.85 (s, 8H), 8.14 (d, J = 5.5 Hz, 8H), -2.95 (s, 2H).

1c) Alkylation step

10 70 mg (0.1 mmol) of 5-(2,3,4,5,6-pentafluorophenyl)-10,15,20-tris(4-pyridyl)porphyrin (compound **1e**) or any of the other derivatives **1b** - **1f** were stirred at room temperature with 3 mL (48 mmol) CH₃I in 10 mL DMF for 12 hours, after which the reaction mixture was evaporated to dryness by high vacuum at room temperature. The resulting crystals were recrystallized from mixtures of MeOH and EtOAc, thus
15 obtaining:

2b 5,10,15-tris(2,3,4,5,6-pentafluorophenyl)-20-(N-methyl-4-pyridylium)porphyrin iodide: UV-vis (H₂O): λ_{max} (nm) 418, 516, 582.

2c (compound P17)


5,15-bis(2,3,4,5,6-pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylium)porphyrin
20 diiodide: UV-vis (H₂O): λ_{max} (nm) 418, 514, 580.

2d (compound P18)

5,10-bis(2,3,4,5,6-pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylium)porphyrin
diiodide: UV-vis (H₂O): λ_{max} (nm) 416, 514, 582.

2e (compound P16)

25 5-(2,3,4,5,6-pentafluorophenyl)-10,15,20-tris(N-methyl-4-pyridylium)porphyrin triiodide: UV-vis (H₂O): λ_{max} (nm) 420, 516, 584; ¹H NMR (DMSO-*d*₆): δ 9.48 (d, J = 6.5 Hz, 6H), 9.44 (d, J = 5.4 Hz, 2H), 9.17 (m, 6H), 9.02 (d, J = 6.5 Hz, 4H), 8.99 (d, J = 6.5 Hz, 2H), 4.71 (s, 9 H), -3.13 (s, 2H); ¹⁹F NMR (DMSO-*d*₆): δ -139.3 (dd, J_1 = 24.5 Hz, J_2 = 5.8 Hz, 2H), -153.4 (t, J = 22.2 Hz, 1H), -162.2 (J_1 = 23.0 Hz, J_2 = 5.1 Hz,
30 2H).

[I] Example 2Preparation of 5,10,15,20-Tetrakis[4-(N-methyl-2-pyridyl) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide [P20]5 2a) Preparation of the precursor 5, 10, 15, 20-tetrakis[4-(2-pyridyl)-2, 3, 5, 6-tetrafluoro-phenyl]porphyrin

10 1 mL of an 1.6 M n-BuLi solution (1.6 mmol) was added to a stirred solution of 0.14 mL (1.5 mol) 2-bromopyridine in 8 mL of dry THF under an argon atmosphere at -78°C, at such a rate that the temperature of the reaction mixture did not exceed -70°C. After the addition was complete, the reaction mixture was stirred for 1 h at -78°C, resulting in a clear yellow solution. Next, a solution of 0.1 g (0.1 mmol)

15 5,10,15,20-tetrakis(2,3,4,5,6-pentafluorophenyl)porphyrin in 5 mL of dry THF was added dropwise. The mixture was stirred for 3 h at -78°C, and then hydrolyzed with saturated aqueous bicarbonate solution. The layers were separated, the aqueous layer washed with ether, and the combined ether extracts were dried and evaporated to a solid residue.



20 The product was purified by column chromatography on silica gel (2:1 EtOAc:Hexane) and recrystallized from EtOAc:EtOH to give 26-30 mg (20-25% yield) of the pure product as violet solids.

¹H NMR (CDCl₃): δ 9.06 (s, 8H), 8.97 (d, *J* = 3.9 Hz, 4H), 8.03 (t, *J* = 7.7 Hz, 4H), 7.89 (d, *J* = 7.5 Hz, 4H), 7.54 (t, *J* = 6 Hz, 4H), -2.82 (s, 2H). ¹⁹F NMR (CDCl₃):

25 δ-137.57 (q, *J* = 24.8 Hz, 8F), 144.11 (q, *J* = 24.6 Hz, 8F). MS⁺ (*e/z*) 1211.4 (MH⁺, 100%), MS⁻ (*e/z*) 1208.3 ([M-H]⁻, 100%).

The reaction mixture gave more products (~50 mg) that eluted from the column after the desired product, with EtOAc as eluent. The main product from that mixture gave the following spectrum, indicative of more than one pyridyl ring per perfluoro ring.:
 ^1H NMR (CDCl_3): δ 9.19 (d), 9.06 (s), 8.97(d), 8.52(d), 8.43(d), 8.0-7.0 (m), -2.79 (s).
 ^{19}F NMR (CDCl_3): δ -116.0 (d, 1F), -131.5 (d, 1F), -137.6(m, 8F), -144.2 (m, 8F), -145.0 (q, 1F).

2b) Alkylation step






The end product **P20** was obtained by alkylation of the precursor of (2a) above. Thus, a mixture of 40 mg (33 μmol) of 5,10,15,20-tetra[4-(2-pyridyl)-2,3,5,6-tetrafluorophenyl]porphyrin of step 2a and 2.5 ml (40 mmol) of CH_3I in 6 mL of freshly distilled DMF was heated to 70°C for 5h. After evaporation of the solvent the product recrystallized from MeOH:Ether to give 55 mg (95% yield) of the title compound **P20** as violet solids.

UV - vis (H_2O): λ_{max} nm ($\epsilon \times 10^3$) 410 (238), 508 (17.6), 574. ^1H NMR ($\text{DMSO}-d_6$): δ 9.70 (s, 4H), 9.59 (s, 4H), 9.52 (d, $J = 5.8$ Hz, 4H), 9.04 (t, $J = 7.4$ Hz, 4H), 8.79 (d, $J = 7.6$ Hz, 4H), 8.54 (t, $J = 6.8$ Hz, 4H), 4.72 (s, 12H), -3.05 (s, 2H). ^{19}F NMR ($\text{DMSO}-d_6$): δ -137.23 (m, 8F), 137.68 (m, 8F).

[I] Example 3.

Preparation of 5-(2,3,5,6-tetrafluoro-4-N-propylamineaniline)-10,15,20-tris (N-methyl-4- pyridylium iodide) porphyrin [P 19]



A mixture of 66 mg (58 μmol) 5-(2,3,4,5,6-pentafluorophenyl)-10,15,20-tris(N-methyl-4-pyridylium iodide)porphyrin and 0.1 mL (1.2 mmol) of 1,3-diaminopropane was dissolved in 9 mL of freshly distilled DMF and stirred overnight at room temperature. After evaporation of the solvent the product recrystallized from MeOH:Ether to give 60 mg (87% yield) of the title compound.

UV - vis (H_2O): λ_{max} nm ($\epsilon \times 10^3$) 422 (176), 518 (13), 582. ^1H NMR ($\text{DMSO}-d_6$): δ 9.46 (d, $J = 5.6$ Hz, 6H), 9.14 (m, 8H), 8.99 (dd, $J_1 = 12.7$ Hz, $J_2 = 5.8$ Hz, 6H), 4.71 (s, 9H), 3.65 (d, 2H), 2.93 (t, 2H), 1.98 (t, 2H), -3.10 (s, 2H). ^1H NMR (D_2O): δ 9.10 (d, $J = 5.4$ Hz, 6H), 8.73 (bs, 6H), 3.59 (t, $J = 6.9$ Hz, 2H), 3.11 (t, $J = 7.5$ Hz, 2H), 2.05 (t, $J = 7.4$ Hz, 2H). ^{19}F NMR ($\text{DMSO}-d_6$): δ -142.9 (d, $J = 19.4$ Hz, 2F), 160.5 (d, $J = 20.4$ Hz, 2F).

[I] Example 4

15 Synthesis of tetrakis(N-methyl-4-pyridyl iodonyl) aluminium porphyrin [P6]

4a) Preparation of precursor tetrakis(4-pyridyl)porphyrin

Freshly distilled 4-pyridylaldehyde and pyrrole (1:1) were refluxed in propionic acid for 2 hrs. The solvent was removed by distillation from the reactive flask under reduced pressure. The oily black residue was washed with hot water, neutralized with aqueous NH_4OH and then washed with DMF to remove the by-products. The purple precipitate was purified by means of multiple crystallization and recrystallization. Yield: 12%. The product was characterized by ^1H NMR, UV and MS.

4b) Preparation of tetrakis(4-pyridyl) aluminium porphyrin

The mixture of the product of step 4a, $\text{Al}(\text{acac})_3$, and phenol, was heated in a pressure flask up to 230°C for 2.5 hrs. The reactive mixture was allowed to cool to room temperature and washed with 2N NaOH and distilled water until pH neutral. Yield 78%.

4c) Preparation of aluminium tetrakis(N-methyl-4-pyridyl iodonyl) porphyrin [P6]

1 mmol solution of the product of step 4b in DMF was stirred with excess of methyl iodide at room temperature for 3 hours. The solvent was evaporated and the residue was then recrystallized twice from methanol-ether. Yield 90%.

[I] Example 5.

Synthesis of tetrakis(N-methyl-2-pyridyl iodonyl) porphyrin [P7]

5a) Preparation of 5,10,15,20-tetrakis(2-pyridyl)porphyrin

The procedure is the same as described in Example 4a above for the 4-pyridyl compound but the purification and isolation procedures are different. Unlike the 4-analogue, this porphyrin dissolves in DMF, so the isolation and purification have been done through the use of column chromatography on Floricil for initial isolation of the target product from black precipitate and then with use of Silica Gel column for purification of the compound. The further crystallization and multiple recrystallization led to the pure target product.

5b) Preparation of zinc tetrakis(2-pyridyl)porphyrin

To the refluxing mixture of the product of step 5a in DMF, acetate salt of zinc was added and the mixture was stirred for an additional 15 min. Then the flask was cooled and the purple precipitate was washed with methanol and ether. Yield 90%. This Zn-porphyrin was prepared in order to protect the core N-H atoms from possible methylation.

5c) Methylation

Methylation of the product of step 5b was performed as described for the 4-analogue in Example 4c with methyl iodide. Methylation of the Zn-porphyrin was

done as with free-base porphyrin. The NMR shows that core N-H doesn't undergo any methylation in the free base compound.

5d) Deprotection from Zn

Deprotection from Zn was done by extraction with 1% HCL. The product obtained after deprotection contains 9% of unrecognized compound. No purification was done because the target product was already obtained by direct methylation of the free-base porphyrin.

The non-charged intermediate of step 5a and the end product P7 were characterized as follows: 5,10,15,20-tetrakis(2-pyridyl)porphyrin: UV-vis (CH₂Cl₂): λ_{\max} (nm) 416, 512, 588; ¹H NMR (CDCl₃): δ 9.13 (m, 4H), 8.85 (s, 8H), 8.18 (m, 4H), 8.11 (m, 4H), 7.70 (m, 4H), -2.84 (s, 2H).

P7 : UV-vis (H₂O): λ_{\max} (nm) 414 (log ϵ = 5.03), 510, 580.

[I] Example 6

Synthesis of tetrakis(N-methyl-4-pyridyl iodonyl) porphyrin [P8]

The title compound was prepared by methylation with excess of methyl iodide from the free base parent porphyrin and purified by crystallization.

[I] Example 7

Synthesis of tetrakis(N-methyl-4-pyridyl tosyl) porphyrin [P1]

The title compound, as the p-toluenesulfonato salt, was prepared by methylation with excess of methyl p-toluene sulfonate from the free base parent porphyrin by reflux in DMF and purified by crystallization.

[I] Example 8

Synthesis of tetrakis(N-methyl-2-pyridyl tosyl) porphyrin [P9]

The title compound was prepared by methylation with excess of methyl p-toluene sulfonate from the free base parent porphyrin by reflux in acetone and purified by crystallization.

[I] Example 9**Synthesis of tetrakis(4-carboxyl) porphyrin ammonium salt [P11]**

A mixture of freshly distilled pyrrole and p-carboxyl-benzaldehyde were refluxed in propionic acid for 3 hrs. The precipitated purple crystals were obtained after cooling the mixture, and then it was filtered. The obtained product was of 95% purity. In order to obtain a more pure product the porphyrin was treated by NaHCO₃ and extracted with ethyl acetate and methylene chloride. The organic impurities were transferred into the organic layer whereas the target product as the Na salt was in aq. layer. The further neutralization with HCl to pH<6 led to the formation of crystal acidic porphyrin which was filtered and dried. The green crystals then were treated by 2M ammonia in methanolic solution until the green color changed to the purple one. The title product was crystallized with water-methanol-methylene chloride. Yield 23%.

[I] Example 10**Synthesis of Compounds P12 and P13**

Compounds P12 and P13 are known and were prepared by alkylation with methyl iodide (P13) or methyl toluene sulfonate (P12) of the known non-charged intermediate: 5,10,15,20-tetrakis(3-pyridyl)porphyrin [Chemical Abstract Registry No: 40882-83-5]: ¹H NMR (CDCl₃): δ 9.45 (s, 4H), 9.06 (d, J=5.5 Hz, 4H), 8.85 (s, 8H), 8.52 (d, J=7.8 Hz, 4H), 7.77 (dd, J₁=7.8 Hz, J₂=5 Hz, 4H), -2.86 (s, 2H). P13 5,10,15,20- tetrakis(N-methyl- 3- pyridylum) porphyrin tetraiodide: UV-vis (H₂O): λ_{max} (nm) 416, 514, 582.

[I] Example 11**Preparation of 5,10,15-tris[4-(N-methyl-2-pyridylum iodide)-2,3,5,6- tetrafluoro phenyl]corrole [P21]****11a) Preparation of intermediate 5,10,15-tris(4-(2-pyridyl)-tetrafluorophenyl) corrole.**

0.42 mL of an 1.6 M n-BuLi solution (0.7 mmol) was added to a stirred solution of 0.054 mL (0.56 mmol) 2-bromopyridine in 6 mL of dry THF under an argon atmosphere at -78°C, at such a rate that the temperature of the mixture did not exceed –

70°C. After the addition was complete, the reaction mixture was stirred for 1h at -78°C, to give a clear yellow solution. Next, a solution of 0.03 g (0.038 mmol) 5,10,15-tri(2,3,4,5,6-pentafluorophenyl)corrole in 6 mL of dry THF was added dropwise. The mixture was stirred for 1h at -78°C and then hydrolyzed with saturated aqueous bicarbonate solution. The layers were separated, the aqueous layer washed with ether, and the combined ether extracts were dried and evaporated to a solid residue.

The product was purified by column chromatography on silica gel (1:1 EtOAc:Hexane) and recrystallized from CH₂Cl₂ : hexane to give 13 mg (35% yield) of the pure product as violet crystals.

UV - vis (CH₂Cl₂): λ_{\max} nm 414 (111.6), 564 (18.4), 606. ¹H NMR (CDCl₃): 9.12 (d, *J*=3.9 Hz, 2H), 8.93 (m, 5H), 8.73 (d, *J*=4.88 Hz, 2H), 8.66 (d, *J*=3.91 Hz, 2H), 8.00 (dt, *J*¹=7.81 Hz, *J*²=1.95 Hz, 3H), 7.84 (bd, *J*=7.81 Hz, 3H), 7.51 (dt, *J*¹=6.84 Hz, *J*²=1.95 Hz, 3H), -2.02 (bs, 3H). ¹⁹F NMR (CDCl₃): -138.19 (q, *J*=23.79 Hz, 2F), -138.81 (q, *J*=23.79 Hz, 4F), -144.11 (q, *J*=23.79 Hz, 4F), -144.57 (q, *J*=23.79 Hz, 2F). MS⁺ (*m/z*) 972.9 (MH⁺, 100%), MS⁻ (*m/z*) 972.7 ([M-H]⁻, 100%).

11b) Preparation of title Compound P21

A mixture of 11 mg (11 μ mol) of 5,10,15-tri(4-(2-pyridyl)-2,3,5,6-tetrafluorophenyl)corrole prepared in step 11a and 0.8 mL (13 mmol) of CH₃I in 2 mL of freshly distilled DMF was heated to 70°C for 3h. After evaporation of the solvent the product was recrystallized from MeOH:Ether to give 15.5 mg (98% yield) of the title compound as green solids.

UV - vis (MeOH): λ_{\max} nm ($\epsilon \times 10^3$) 430 (76.2), 576 (10.9), 622 (17.8). ¹H NMR (DMSO-*d*₆): 9.49 (d, *J*=5.98 Hz, 3H), 9.16 (bm, 8H), 9.00 (t, *J*=8.54 Hz, 3H), 8.75 (t, *J*=7.68 Hz, 3H), 8.51 (t, *J*=7.68 Hz, 3H), 4.68 (s, 3H), 4.65 (s, 6H). ¹⁹F NMR (DMSO-*d*₆): d-137.26 (bm, 4F), -138.04 (bm, 6F), -138.60 (bm, 2F).

II BIOLOGICAL SECTION

MATERIALS

Human recombinant bFGF was from American Cyanamid (Pearl River, NY); heparin-coated plates were from Carmeda (Sweden); FRAP was prepared as described (Ornitz et al, 1992); NIH 3T3 cells expressing signal peptide bFGF were generated as

described (Yayon and Klagsbrun, 1990); anti-FGFR3 antibody and anti-phosphotyrosine antibody PY-20 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA); anti-ERK 1,2 antibody was purchased from Sigma; DMEM was from Bet Haemek Biological Industries (Israel); compounds **P1, P2, P3, P4, P5** were either synthesized or purchased from Aldrich (catalog Nos 32,349-7, 25,292-1, 25,288-3, 41,206-6, 30,678-9, respectively); human recombinant VEGF was generated by H. Weich, Braunschwig (Germany); anti-AP antibodies were prepared as previously described (Ornitz et al, 1992).

10 **METHODS**

(i) **Animals and Treatment.** Male Balb/C nude and C57/black mice were maintained on lab chow and tap water and were housed with a 12-h day-night cycle.

15 (ii) **Binding of soluble FGFR-1 alkaline phosphatase fusion protein (FRAP) to immobilized bFGF.** A high throughput screening system composed of a heparin matrix, bFGF and FGFR-1 tagged by alkaline phosphatase (FRAP), was designed using 96-well plates to which heparin has been covalently attached. bFGF was then bound to immobilized heparin, followed by the addition of FRAP and the compounds to be
20 screened for testing their ability to modulate heparin-FGF, receptor-heparin and receptor-FGF interactions. The end-point of the assay measured enzymatically the formation of FGF-receptor complexes quantitated by the specifically associated alkaline phosphatase (AP) catalyzed chromogenic product. Thus, a lowered or elevated AP value, relative to a control, indicates modulation of binding at one or more of the three
25 levels of interactions required for the formation of the FGF-FGFR-heparin ternary complex (a lowered AP activity indicates inhibition). bFGF (100 ng/ml) was incubated on 96-well plates to which heparin has been covalently attached (Carmada, Sweden). Subsequently, 200 µl of FRAP condition medium and porphyrin/corrole compound were added and incubated together for 2h. After three cycles of washing with HNTG (20 mM
30 Hepes pH 7.5, 150 mM NaCl, 1% Triton X-100 and 10% glycerol), alkaline phosphatase substrate (Sigma) (15mM) was added and catalyzation of the chromogenic product was measured by spectrophotometry at 405 nm.

(iii) **Binding of ^{125}I -bFGF or ^{125}I -FGF9 to soluble FGFR-1 or FGFR-3.** Conditioned medium from NIH 3T3 cells secreting soluble FRAP or FGFR-3 FR-3-AP, was incubated for 45 min at room temperature with rabbit anti-human placental AP antibodies (generated as described in Ornitz et al, 1991) prebound to agarose-protein A beads (Pierce). The FGFR-1 or FGFR-3-coupled beads were washed three times with 1 ml HNTG and incubated with 2 ng/ml of ^{125}I -FGF, 1 $\mu\text{g}/\text{ml}$ of heparin and porphyrin/corrole compound at different concentrations for 1h at room temperature. High affinity-bound ^{125}I -bFGF was determined by counting of the samples in a γ -counter.

(iv) **Binding of ^{125}I -bFGF and ^{125}I -FGF9 to cells.** Confluent cultures of CHO cells expressing FGFR-1(Yayon et al, 1991) or FGFR-3 (Hecht et al, 1995) in 24-well plates (Falcon) were precooled and washed twice with cold DMEM supplemented with 20 mM Hepes (pH 7.5) and 0.1% bovine serum albumin (DMEM/BSA). They were then incubated for 1.5 h at 4°C with ^{125}I -bFGF (2 ng/ml) and increasing concentrations of porphyrin/corrole compound. The binding medium was discarded and the cells were washed once with ice-cold DMEM/BSA and twice with cold PBS (pH 7.5) containing 1.6M NaCl. High-affinity receptor-bound bFGF was determined by extraction of the cells with 20 mM Na acetate pH 4.0 containing 2.0 M NaCl. Non-specific binding was determined in the presence of a 100-fold excess of unlabeled bFGF.

(v) **Inhibition by porphyrins of tumor formation induced by signal peptide bFGF expressing cells.** NIH 3T3 cells expressing signal peptide bFGF were injected subcutaneously to Balb/C nude mice as described (Yayon and Klagsbrun, 1990). Porphyrin/corrole compound at 25 $\mu\text{g}/\text{g}$ of body mass was injected IP (intraperitoneally) twice a week and after 4 weeks the tumor size was measured.

(vi) **Rat aorta *in vitro* angiogenesis assay.** Rings of rat aorta sections were immobilized in a three-dimensional collagen gel, in the presence of serum free growth medium (DMEM) (Nicosia & Ottinetti, 1990). Porphyrin or corrole compound and bFGF (2 ng/ml) were added to the growth medium twice a week when indicated. After

14 days the cultures were fixed, and the extent of microvascular endothelial tube outgrowth was measured under a light microscope (Miao et al., 1997).

(vii) **Lewis lung carcinoma tumor assay.** Murine Lewis lung carcinoma (LLC) D122 cells (1×10^6 cells/50 ml PBS) were injected into the foot pads of 10-week old C57 black mice (O'Reilly et al, 1994). Twenty five $\mu\text{g/g}$ of body mass of porphyrin or corrole compound dissolved in PBS were injected IP twice a week to the treated group, and tumor size was measured periodically in order to follow primary tumor formation. In order to evaluate inhibition of lung metastasis by porphyrin or corrole compound, the primary tumors were allowed to develop over a period of six weeks to a volume of approximately 8 mm^3 ; after which the tumors were removed and metastases were allowed to develop for four weeks. During this time the treated group received $25 \mu\text{g/g}$ of body mass of porphyrin or corrole compound IP twice a week. Subsequently the mice were sacrificed, dissected and the lungs removed and photographed. The extent of lung metastasis was measured by weighing the lungs.

(viii) **Immunoblots.** To the overnight serum-starved cells (2 plates for each treatment), $500 \mu\text{l}$ of F12^{++} medium were added which either contained or not the respective porphyrin or corrole compound in a final concentration of $1 \mu\text{ml}$ for 40 min at 37°C . One of the two plates of each treatment was then stimulated with FGF9 (+) (75 ng/ml) and to the second plate only medium (-) was added for 10 min at 37°C . The cells were washed twice with PBS. $600 \mu\text{l}$ of SBN lysis buffer containing 1% NP-40 and 1 mM vanadate were added and left on ice for 10 min. The plates were then scraped and left on ice for additional 10 min. The lysate was spun down in Eppendorf centrifuge for 15 min, 15000 rpm at 4°C . The supernatants were kept and Bradford protein determination assay was performed in the samples. $500 \mu\text{g}$ protein from each sample were taken for immunoprecipitation with $7.5 \mu\text{l}$ antibody against FGFR-3, 4 hr at 4°C . The immunoprecipitated samples as well as total lysates ($40 \mu\text{g}$) were separated on 7.5% polyacrylamide SDS-PAGE and then transferred to nitrocellulose paper and immunoblotted with the subsequent antibodies.

(ix) **Binding of soluble VEGF receptor alkaline phosphatase fusion protein to immobilized VEGF.** The flt-1 VEGF receptor was expressed as a fusion protein with AP as previously described (Roeckl et al, 1998) and tested for its binding capacity to immobilized VEGF as described in method (ii) above for the FGF receptor.

5

(x) **Binding of ^{125}I -VEGF to cells.** Confluent cultures of bovine aortic endothelial cells transfected with the VEGF receptor KDR were tested for binding of radiolabeled ^{125}I -VEGF as described in method (iv) above for the FGFR-1 expressing cells.

10 [II] **Example 1. Compound P1 inhibits binding of bFGF to FGFR-1 *in vitro***

In order to identify inhibitors of FGF-FGFR interactions, an assay for testing FGFR-ligand binding was developed. The system is composed of bFGF bound to a heparin matrix to which soluble FGFR-1 ectodomain alkaline phosphatase fusion protein (FRAP) and the screened compounds are added (see Methods, section (ii)). The
15 screening according to the invention identified several compounds for their capacity to inhibit soluble FGF receptor (FRAP) binding to FGF immobilized on heparin, the first and very potent one being Compound P1.

For evaluation of the capacity of P1 to inhibit bFGF-induced activity, its ability to inhibit bFGF binding to FGFR-1 was first tested in *in vitro* systems. P1 was tested
20 for its capacity to inhibit binding of FRAP to bFGF immobilized on heparin matrix. As shown in Fig. 1A, P1 demonstrated potent inhibition at IC_{50} of 90 ng/ml, with a distinct dose-dependent inhibition pattern.

In order to further examine the capacity of P1 to inhibit bFGF receptor binding, we measured the binding of radiolabeled ^{125}I -bFGF to FGFR in two experimental
25 systems. First we utilized a cell-free system, measuring the binding of radiolabeled bFGF to a dimeric soluble FGFR-1 fused to alkaline phosphatase. The soluble FRAP was immobilized using an anti-alkaline phosphatase antibody prebound to agarose-protein A beads (see Methods, section (iii)). As a second experimental model, we used CHO cells deficient in heparan sulfate and genetically engineered to express
30 FGFR-1 (Methods, section (iv)). P1 inhibited binding of ^{125}I -bFGF to the FGF receptor in both experimental systems. Fig. 1B illustrates that the porphyrin P1 is capable of profoundly inhibiting bFGF-FGFR1 binding in the soluble receptor (FRAP) assay in a

dose dependent manner with an IC₅₀ of about 1 μ M. In the cellular receptor system, P1 was capable of inhibiting bFGF binding with an IC₅₀ of approximately 2.5 μ M (Fig. 1C). The slightly higher concentrations of P1 required for inhibition of cellular bFGF binding in the cellular assay may result from the reduced affinity of the soluble FGFR to the FGF ligand (Ornitz et al, 1992).

[II] Example 2. Inhibition of covalent cross-linking of ¹²⁵I-bFGF and ¹²⁵I-FGF9 to CHO cells by Compound P1

In order to unequivocally determine the specificity of the binding inhibition, chemical cross-linking of ¹²⁵I-bFGF and ¹²⁵I-FGF9 to CHO cells transfected with FGFR-1 and FGFR-3, respectively, was carried out as described in Methods, section (iv), in the absence or presence of increasing concentrations of P1. As shown in Fig. 2, P1 can inhibit bFGF receptor binding as demonstrated by the inhibition of formation of a typical bFGF-receptor complex, in agreement with the direct binding data shown in Fig. 1C. Suramin, a well known tyrosine kinase inhibitor, served as a positive control and demonstrated FGF receptor binding inhibition. These results support the notion that the presence of P1 inhibits the binding of bFGF to the high affinity FGF tyrosine kinase receptors.

[III] Example 3. Inhibition of *in vitro* angiogenesis by Compound P1

The effect of P1 was further examined in a biological assay for angiogenesis *in vitro*. Angiogenic vascularization is a process in which bFGF is known to play a pivotal role (Folkman, 1989). To examine the inhibitory effects of the porphyrin on bFGF-promoted angiogenesis, we employed an *in vitro* angiogenic assay using rat aorta sections embedded in a collagen gel (Methods, section (vi)). The assay measures the extent of endothelial cell growth and microvascular tubules sprouting from the vessel tissue embedded in the gel. Basal tubule formation can be detected even when no additional factors are added. As shown in Fig. 3, the addition of 2 ng/ml bFGF alone dramatically increased the degree of cell growth and vascularization, however the addition of 2 ng/ml bFGF combined with P1 at concentrations of 10 μ M dramatically reduced the extent of endothelial cell growth as compared to the bFGF control. When

100 μ M P1 was added in the presence of 2 ng/ml bFGF, complete inhibition of microvascular tubules was achieved and no endothelial cell growth was observed.

[II] Example 4. Tumor formation induced by signal peptide bFGF expressing cells is inhibited by Compound P1

After establishing the ability of P1 to inhibit FGF biological activity *in vitro*, the capacity of P1 to inhibit bFGF-induced tumor growth and metastasis was evaluated *in vivo*. First, the inhibition of tumor growth induced by signal peptide bFGF in a nude mice model was measured (Methods, section (v)). Upon addition of a signal peptide residue to bFGF, the protein is capable of transforming NIH 3T3 cells which, when injected to nude mice, grow and form a tumor (Yayon & Klagsbrun, 1990). NIH 3T3 cells expressing signal peptide bFGF were injected subcutaneously to Balb/C nude mice, and P1 either free or liposome incorporated (as described by Jori and Reddi, 1993) (25 μ g/g of body mass) were given twice a week by intraperitoneal injection. After 4 weeks, a clear inhibition of tumor formation by the free P1 could be seen (Fig 4). These results indicated that P1's capacity to inhibit bFGF receptor binding was not limited to *in vitro* interactions alone but could be shown in *in vivo* assays as well.

[III] Example 5. Compound P1 inhibits the appearance of primary tumors in the Lewis lung carcinoma (LCC) tumor model

Inhibition of primary tumor growth was tested using the well-established LLC murine tumor growth and metastasis model (Methods, section (vii)). LLC D122 cells (200,000 cells per mouse) were injected into the foot pads of 10-week old C57 black mice. Mice having received Compound P1 (25 μ g/g of body mass) by intraperitoneal (IP) injections twice a week, as described in Methods, section (vii), for 5 weeks, showed a marked inhibition in primary tumor growth in comparison to the control group (Fig. 5). The inhibition of the foot pad primary carcinoma tumor growth was statistically established and reproducible in five experiments. These results indicate that P1 is not only active *in vitro*, but it is capable of inhibiting tumor growth *in vivo* as well.

[III] Example 6. Compound P1 inhibits lung metastasis in the Lewis lung carcinoma model

After establishing the capacity of P1 to inhibit primary tumor growth, the capacity of P1 to inhibit lung metastasis formation was measured as described in Methods, section (vii). Mice were injected with LLC cells (200,000 cells per mouse) into the foot pad and primary tumors were allowed to develop over a period of 3 to 4 weeks to a volume of approximately 8 mm³. Subsequently, primary tumors were removed through amputation and lung metastases were allowed to develop for four weeks before the mice were sacrificed. The extent of lung metastasis at this point was examined by gross morphological examination and by determining the gain in lung weight. Fig. 6 shows that, as expected, aggressive metastasis formation occurred in the non-treated mice, while in the mice that were treated with Compound P1 (25 µg/g of body mass), the lungs were similar to the control mice, with no metastatic phenotype (Fig. 6). In order to quantitate the results from these experiments, the lungs from all mice were weighed and evaluated for the extent of metastatic growth. As can be seen in Fig. 7, the control lungs from mice who were not injected with tumor cells weighed around 200 mg as do the lungs from mice treated with P1.

[III] Example 7. Inhibitory effects of porphyrins and corroles on the binding of bFGF to EGFR-1 *in vitro*

Porphyrin compounds P2-P20 and corrole compound P21 were tested as described in Example 1, according to Methods, sections (ii) and (iii). The results are shown in Table 1 and in Figs. 8A-8B.

As can be seen in Fig. 8A, compounds P15 to P18 were active *in vitro* when tested for inhibition of FRAP binding to immobilized bFGF. The next round of porphyrins were tested for their capacity to inhibit radiolabeled bFGF binding to immobilized receptor. As shown in Fig 8B, P16 and P18 inhibited the binding of bFGF with an activity over 100 fold higher than that of P1, indicating that they might have a high potential as bFGF inhibitors.

[II] Example 8. Inhibitory effects of porphyrins and corroles *in vivo* in the LLC tumor model

Compounds **P1-P21** were tested for capacity to inhibit the appearance of lung metastasis in the LLC model, as described in Example 6. The results are shown in Table 2 and in Fig. 9. Compounds **P16-P18** were not as potent as the lead Compound **P1** while **P5** and **P7** had a similar activity as **P1** (Fig. 9). Compounds **P20** and **P21**, shown in Example 7 (Fig. 8B) to inhibit bFGF binding *in vitro*, were also shown here to be highly active *in vivo* in the LLC tumor model (Table 2).

[II] Example 9. Compound P1 inhibits the binding of VEGF to VEGF-R

Since both FGF and VEGF share several similar characteristics, such as the requirement of heparin for binding to the receptor (Gitay-Goren et al, 1993) and they may play a synergistic role in tumor angiogenesis, the capacity of **P1, P7, P15, P16, P18** to inhibit VEGF binding to its receptors was evaluated. Figure 10A shows that **P1** efficiently inhibits ^{125}I -VEGF binding to cells highly expressing the KDR/flk-1 VEGF receptor with high potency and has an inhibitory effect similar to that caused by unlabeled VEGF. **P1** inhibits VEGF binding to bovine endothelial cells expressing VEGF receptors in a manner similar to the KDR/flk-1-transfected cells (Methods, section x). As can be seen in Fig. 10B, while **P1** demonstrated an IC_{50} around $0.04\ \mu\text{M}$, compounds **P15** to **P18** were less potent with IC_{50} around $1\ \mu\text{M}$, when tested *in vitro* for inhibition of the VEGF receptor flt-1-AP binding to immobilized VEGF, as described in Methods, section (ix).

[II] Example 10. Porphyrin P16 inhibits the binding of FGF-9 to FGFR-3

To test the porphyrins for their potential ability to be used for the treatment of FGF receptor-related growth disorders, their activity in FGFR-3 related systems was tested.

The capacity of the porphyrins **P1, P7, P15, P16, P17** and **P18** to inhibit FGF-9 induced activity was evaluated by first testing their capability to inhibit FGF-9 binding to FGF receptors in *in vitro* systems. Thus, the compounds were tested for their capacity to inhibit binding of a soluble FGFR-3 ectodomain alkaline phosphatase fusion protein (FR-3-AP) to FGF-9, utilizing a cell free system, similar to the one described for

FGFR-1 in Example 1 above, and measuring the binding of radiolabeled ^{125}I -FGF-9 to soluble FGFR-3. As shown in Fig. 11, the porphyrins are capable of profoundly inhibiting FGF-9 / FGFR-3 binding in the soluble receptor assay in a dose dependent manner with an IC_{50} of $0.1 \mu\text{g/ml}$, with P15 and P16 being more potent.

5 As a second experimental model, CHO cells genetically engineered to express FGFR-3 were used (Hecht et al, 1995). As shown in Fig. 12, also in the cellular receptor system, P16 was more potent, being capable of inhibiting FGF-9 binding with an IC_{50} of $0.1 \mu\text{g/ml}$.

10 [III] Example 11. Porphyrins P1 and P16 inhibit mitogenic activity of FGFR-3 expressing cells induced by FGF-9.

CHO cells genetically engineered to express FGFR-3 were used in order to determine the ability of the porphyrins P1 and P16 to inhibit biological activity of FGFR3 as measured by the level of DNA synthesis induced by FGF-9. As can be seen in
15 Fig. 13, both P1 and P16 had a strong inhibitory effect on the cell proliferation induced by FGF-9, indicating that both porphyrins, more particularly P16, may serve as inhibitors of FGFR-3 unregulated activity.

20 [III] Example 12. Porphyrin P16 inhibits FGFR-3 tyrosine phosphorylation in cells induced by FGF-9.

FGFR-3 tyrosine phosphorylation is a distinct parameter of biochemical activation of the receptor leading to signal transduction in the cell nucleus and resulting in biological activity. Measuring the phosphorylation level allows a direct judgment as to the ability of an inhibitor to effect receptor activation.

25 In order to measure the ability of the porphyrins to inhibit the receptor activation on an enzymatic level as well, FGFR-3 tyrosine phosphorylation was measured in the presence of P16, as described in Methods, section (viii). Immunoprecipitation of FGFR-3 with the anti-FGFR-3 antibodies and immunoblotting with anti-phosphotyrosine antibodies demonstrated that P16 reduced both the basal and, to a much
30 greater extent, the FGF-9 induced phosphorylation of FGFR-3 (Fig. 14), indicating that P16 has a significant, direct and highly specific effect on FGFR-3 activity.

II Example 13. Porphyrin P16 inhibits PLC- γ and ERK phosphorylation in FGFR-3 expressing cells induced by FGF-9.

Stimulation of FGFR-3 results in a variety of human skeletal genetic defects. The phosphorylated FGFR-3 transduces its signal down stream by transphosphorylation of adaptor proteins which are part of its signaling cascade (Kanai et al, 1997). At least three different FGFR-3 signaling pathways have been identified: 1) the ERK/MAP kinase mediated pathway; 2) the STAT kinase mediated pathway; and 3) the phospholipase C-gamma (PLC- γ) mediated pathway. Examining the level of phosphorylation of these signaling proteins allows one to establish the potency of an inhibitor capable of down regulating FGFR-3 dependent signaling.

In order to demonstrate the effect of P16 on the enzymatic signal transduction pathway induced by FGFR-3, phosphorylation of PLC- γ and ERK, two well established players in FGF signaling, was examined in cells expressing FGFR-3. Immunoblotting with anti-PLC- γ antibodies (Fig. 15A) or anti-activated ERK/MAP kinase antibodies (Fig. 15B), respectively, demonstrated clear reduction in the activation of both signal-mediating proteins by P16. These findings support the notion that the porphyrins can serve for treating FGFR-3 related growth disorders. ERK1 and ERK2 are two isoforms of ERK.

II Example 14. P1 inhibits smooth muscle cells proliferation induced by bFGF.

In order to determine the ability of P1 to inhibit the biological activity of bFGF on cell proliferation, smooth muscle cells were grown in 24-well plates in the presence of bFGF (10 ng/ml) and in the presence of 2 μ g/ml or 20 μ g/ml of P1. Cell number was determined daily by counting cell samples under a microscope. As can be seen in Fig. 16, P1 had a strong inhibitory effect on smooth muscle cell proliferation induced by bFGF. These results suggest that P1 may serve as an inhibitor of smooth muscle cells causing restenosis.

TABLE 1: Inhibitory activity *in vitro* (IC₅₀ in μ M) of compounds P1-P21 on binding of FGF to FGFR

<u>Compound</u>	<u>Cellular receptor binding⁽¹⁾</u>	<u>Soluble receptor binding⁽²⁾</u>	<u>Screen AP assay⁽³⁾</u>
P1	1.5	0.75	0.075
P2	ND	ND	NA
P3	ND	ND	NA
P4	ND	ND	NA
P5	1.8	0.9	0.1
P6	1,8	0.7	0.09
P7	2	0.8	0.07
P8	1.3	0.95	0.095
P9	5.5	3	NA
P10	1.9	0.85	0.08
P11	NA	ND	0.5
P12	NA	10	ND
P13	NA	NA	ND
P14	3	0.85	ND
P15	0.12	0.08	ND
P16	0.02	0.01	ND
P17	0.03	0.02	ND
P18	0.1	0.075	ND
P19	2	ND	0.1
P20	0.2	ND	0.03
P21	1	ND	ND

5 (1) Assay according to Methods, section (iv)

(2) Assay according to Methods, section (iii)

(3) Assay according to Methods, section (ii)

ND - not determined; NA - not active at 10 μ M

TABLE 2: Inhibitory Activity *in vivo* of Compounds P1-P21 in the LLC murine tumor model. (as % of total Inhibition at 25 µg/gram)



<u>Number</u>	<u>LLC tumor model</u>
P1	100
P2	ND
P3	ND
P4	ND
P5	75
P6	ND
P7	90
P8	90
P9	ND
P10	ND
P11	ND
P12	0
P13	ND
P14	90
P15	ND
P16	60
P17	40
P18	50
P19	ND
P20	150
P21	200

5


ND – not determined

APPENDIX A – Structures of Compounds P-1–P-21


P-1




P-2




P-3




P-4




P-5




P-6




P-7

 $R^- = I^-$


P-8

 $R^- = I^-$


P-9

 $R^- = ^-O_3S-C_6H_4-CH_3$


P-10





P-11




P-12



P-13




P-15




WO 00/27379

PCT/IL99/00602


P-19



P-20



P-21



REFERENCES

1. Aloe L, Bracci-Laudiero L, Bonini S, Manni L (1997) The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy 52(9):883-94.
2. Aviezer, D., Levy, E., Safran, M., Svahn, C., Buddecke, E., Schmidt, A., David, G., Vlodavsky, I. and Yayon, A. (1994a). Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem, 269, (1) 114-21.
3. Aviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G. and Yayon, A. (1994b). Perlecan, basal lamina proteoglycan, promotes bFGF-receptor binding, mitogenesis and angiogenesis. Cell, 79, 1005-1013.
4. Aviezer, D. and Yayon, A. (1994). Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci U S A, 91, (25) 12173-7.
5. Connor B, Dragunow M (1998) The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev ;27(1):1-39.
6. Deng, C., Wynshaw, B.A., Zhou, F., Kuo, A. and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell, 84, (6) 911-21.
7. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korblik M, Moan J, Peng Q (1998) Photodynamic Therapy J Natl Cancer Inst ;90(12):889-905.
8. Folkman, J. (1989) Successful treatment of an angiogenic disease. N Engl J Med; 320(18): 1211-2.
9. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59: 99-106, 1999.
10. Frade JM, Barde YA (1998) Nerve growth factor: two receptors, multiple functions. Bioessays 20(2):137-45.

11. Gitay-Goren, H., Soker, S., Vlodavsky, I. and Neufeld, G. (1992). The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. *J. Biol. Chem.*, 267, (9) 6093-6098.
12. Gross Z., Galili N. and Saltsman I. The First Direct Synthesis of Corroles from Pyrrole. *Angew. Chem. Int. Ed. Eng.*, 38, 1427-9, 1999.
13. Guimond, S., Maccarana, M., Olwin, B.B., Lindahl, U. and Rapraeger, A.C. (1993). Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2 and FGF-4. *J Biol Chem*, 268 (32): 23906-14.
14. Hecht, D., Zimmerman, N., Bedford, M., Avivi, A. and Yayon, A. (1995). Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. *Growth Factors*, 12, (3) 223-33.
15. Jori G, Reddi E (1993) The role of lipoproteins in the delivery of tumour-targeting photosensitizers. *Int J Biochem* 10 1369-1375.
16. Jori G, Reddi E, Cozzani I, Tomio L (1986) Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice. *Br J Cancer* 53(5):615-621.
17. Kanai, M., Goke M., Tsunekawa S., Podolsky D.K. (1997). Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein. *J. Biol. Chem.*, 272(10): 6621-8.
18. Klagsbrun, M. (1989). The fibroblast growth factor family: structural and biological properties. *Progress in Growth Factor Research*, 1, 207-235.
19. La, T., Miskelly, G., Bau, R. (1997) *Inorg. Chem.* 36, 5321.
20. Margaron P, Madarnas P, Quellet R, Van Lier JE Biological activities of phthalocyanines. XVII histopathologic evidence for different mechanisms of EMT-6 tumor necrosis induced by photodynamic therapy with disulfonated aluminum phthalocyanine or photofrin. *Anticancer Res.*, 16 :613-20, 1996.
21. Miao HQ, Ornitz DM, Aingorn E, Ben-Sasson SA, Vlodavsky I, Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling and angiogenic activity by a synthetic heparin-mimicking polyanionic compound. *J Clin Invest.*, 99:1565-75, 1997.


22. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. *Science* ;276, :955-60, 1997.
23. Naski, M.C., Wang, Q., Xu, J. and Ornitz, D.M. (1996). Graded activation of
5 fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nature Genetics*, 13, 233-237.
24. Nicosia RF, Ottinetti A, (1990) Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. *Lab Invest* 63(1):115-122.
- 10 25. O'Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., Folkman, J. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. *Cell* 79(2): 315-28.
- 15 26. Ornitz, D.M., Yayon, A., Flangan, J.G., Svahn, C.M., Levi, E. and Leder, P. (1992). Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. *Mol. Cell. Biol.*, 12, 240-247.
27. Ornitz, D.M., Herr, A.B., Nilsson, M., Westman, J., Svahn, C.M. and Waksman, G. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. *Science*. 268, 432-6, 1995.
- 20 28. Patt, S., Danner, S., Theallier-Janko, A., Breier, G., Hottenrott, G., Plate, K.H., Cervos- Navarro, J. (1998) Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat. *Neurosci Lett* 252(3): 199-202.
29. Rapraeger, A.C., Krufka, A. and Olwin, B.B. (1991). Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. *Science*, 252,
25 1705-17.
30. Reardon, W., Winter, R.M., Rutland, P., Puileyn, L.J., Jones, B.M. and Malcolm, S. (1994). Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. *Nature Genetic*, 3, 98-103.
31. Roeckl, W., Hecht, D., Sztajer, H., Waltenberger, J., Yayon, A., Weich, H.A.
30 (1998) Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. *Exp Cell Res*, 241(1): 161-70.

32. Rousseau, F., Bonaventure, J., Legeal-Mallet, L., Pelet, A., Rozet, J.-M., Maroteaux, P., Le-Merrer, M. and Munnich, A. (1994). Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. *Nature*, 371, 252-254.
33. Schlessinger, J., Lax, I. and Lemmon, M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? *Cell*, 83, 357-60, 1995.
34. Shiang, R., Thompson, L.M., Zhu, Y.-Z., Church, D.M., Winokur, S.T. and Wasmuth, J.J. (1994). Mutations in transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, Achondroplasia. *Cell*, 78, 335-342.
35. Ullrich, A. and Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. *Cell*, 61, 203-212.
36. Van de Woude GF, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J (1997) Met-HGF/SF: tumorigenesis, invasion and metastasis. *Ciba Found Symp*; 212:119-130.
37. Yanagawa K, Yamashita T, Yada K, Ohira M, Ishikawa T, Yano Y, Otani S, Sowa M (1998) The antiproliferative effect of HGF on hepatoma cells involves induction of apoptosis with increase in intracellular polyamine concentration levels. *Oncol Rep* 5(1):185-190.
38. Yayon, A. and Klagsbrun, M. (1990). Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: Reversal by suramin. *Proc. Natl. Acad. Sci. USA*, 87, 5346-5350.
39. Yayon, A., Klagsbrun, M., Esko, J.D., Leder, P. and Ornitz, D.M. (1991). Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. *Cell*, 64, 841-848.

CLAIMS

1. A pharmaceutical composition for inhibiting growth factor receptor tyrosine
5 kinase activity comprising a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-
porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a
heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals
are positively charged, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1, wherein said growth
10 factor receptor tyrosine kinase is selected from fibroblast growth factor (FGF) receptor
tyrosine kinase, epidermal growth factor (EGF) receptor tyrosine kinase,
heparin-binding EGF-like growth factor (HB-EGF) receptor tyrosine kinase, platelet
derived growth factor (PDGF) receptor tyrosine kinase, vascular endothelial growth
factor (VEGF) receptor tyrosine kinase, nerve growth factor (VGF) receptor tyrosine
15 kinase, hepatocyte growth factor (HGF) receptor tyrosine kinase, insulin receptor
tyrosine kinase and insulin-like growth factor (IGF) receptor tyrosine kinase.
3. The pharmaceutical composition according to claim 2 for inhibition of cell
proliferation mediated by growth factor receptor tyrosine kinase activity.
4. The pharmaceutical composition according to claim 3 for: (i) inhibition of
20 angiogenesis; (ii) inhibition of vascular smooth muscle cell proliferation in disorders
including atherosclerosis, hypertrophic heart failure and postsurgical restenosis; (iii)
inhibition of cell proliferation and migration in the treatment of primary tumors and
metastasis; (iv) treatment of nonmalignant tumors such as benign prostate hypertrophy;
(v) treatment of diabetic retinopathy, psoriasis, rheumatoid arthritis, and other disorders
25 including retrolental fibroplasia, macular degeneration, hemangioma, arteriovenous
malformation, hypertrophic scars, acne, scleroderma and autoimmune diseases.
5. The pharmaceutical composition according to claim 2 for the treatment of bone
and cartilage related disorders including inherited skeletal disorders, e.g. achondroplasia,
dwarfism, craniosynostosis.
- 30 6. The pharmaceutical composition according to any one of claims 1-5 wherein the
5,10,15,20-tetraaryl-porphyrin has the formula:

5




10

wherein Ar₁, Ar₂, Ar₃, and Ar₄, the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion.

7. The pharmaceutical composition according to any one of claims 1-5 wherein the 5,10,15,20-triaryl-corrole has the formula:

15



20

wherein Ar₁, Ar₂, and Ar₃, the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

8. The pharmaceutical composition according to claim 6 or 7, wherein said carboaryl radical by itself or as part of the mixed carboaryl-heteroaryl radical is a substituted monocyclic or bicyclic aromatic radical and said heteroaryl radical is a substituted 5-6 membered aromatic ring containing 1-3 heteroatoms selected from O, S and/or N.

30

9. The pharmaceutical composition according to claim 8, wherein said carboaryl radical is selected from phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

5 10. The pharmaceutical composition according to claim 9, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C₁-C₈) alkylammonium or amino-(C₁-C₈) alkylamino.

11. The pharmaceutical composition according to claim 10, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-
10 tetrafluorophenyl.

12. The pharmaceutical composition according to claim 10, wherein one to four of said carboaryl radicals is 4-trimethylammonio-phenyl or 4-trimethylammonio-2,3,5,6-tetrafluorophenyl.

13. The pharmaceutical composition according to claim 8, wherein said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, triazinyl substituted by one or more halogen atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

14. The pharmaceutical composition according to claim 13, wherein said one to four of said heteroaryl radicals is N-(C₁-C₈ alkyl)-pyridylum.

15. The pharmaceutical composition according to claim 14, wherein said radical is selected from 2-, 3- or 4-(N-methyl) pyridylum.

16. The pharmaceutical composition according to claim 6 or 7, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylum)-2,3,5,6-tetrafluoro-phenyl.

25 17. The pharmaceutical composition according to any one of claims 1-6, wherein said porphyrin compound is selected from one of the compounds herein designated P1, P5, P6, P7, P8, P9, P10, P15, P16, P17, P18, P19 and P20, namely:

P1 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine tetra-p-tosylate

P5 5,10,15,20-Tetrakis[4-(trimethylammonio)phenyl]-21H,23H-porphine

30 tetra-p-tosylate

P6 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine aluminium hydroxide tetraiodide

- P7** 5,10,15,20-Tetrakis(N-methyl-2-pyridylum)-21H,23H-porphine tetraiodide
- P8** 5,10,15,20-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine tetraiodide
- P9** 5,10,15,20-Tetrakis(N-methyl-2-pyridylum)-21H,23H-porphine tetra-p-tosylate
- P10** 3,8,13,18-Tetrakis(N-methyl-4-pyridylum)-21H,23H-porphine tetraiodide
- 5 **P15** 5,10,15,20-Tetrakis(2,3,5,6-tetrafluoro-4-trimethylammonio-phenyl)-21H, 23H-methyl-porphine tetra-trifluoromethylsulfonate
- P16** 5-Pentafluorophenyl-10,15,20-tris(N-methyl-4-pyridylum)-21H,23H-porphine triiodide
- P17** 5,15-Bis(pentafluorophenyl)-10,20-bis(N-methyl-4-pyridylum)-21H,23H-
10 porphine diiodide
- P18** 5,10-Bis(pentafluorophenyl)-15,20-bis(N-methyl-4-pyridylum)-21H,23H-porphine diiodide
- P19** 5,10,15-Tris(N-methyl-4-pyridylum)-20-(2,3,5,6-tetrafluoro-4-aminopropyl-amino-phenyl)-21H,23H-porphine triiodide
- 15 **P20** 5,10,15,20-Tetrakis[4-(N-methyl-2-pyridylum) 2,3,5,6-tetrafluoro-phenyl]-21H,23H-porphine tetraiodide

18. The pharmaceutical composition according to any one of claims 1-5 and 7 wherein said corrole compound is 5,10,15-Tris[2,3,5,6-tetrafluorophenyl-4-(N-methyl-2-pyridylum)]-21H,23H- corrole triiodide, herein designated **P21**.

20 19. The pharmaceutical composition according to claim 4 for inhibition of angiogenesis comprising the compound **P1** or **P21**.

20. The pharmaceutical composition according to claim 4 for inhibition of vascular smooth muscle cell proliferation in postsurgical restenosis comprising the compound **P1** or **P20**.

25 21. The pharmaceutical composition according to claim 4 for inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis comprising a compound selected from the compounds **P1**, **P5**, **P7**, **P20** and **P21**.

22. The pharmaceutical composition according to claim 5 for inhibition of FGFR-3 tyrosine kinase activity and treatment of achondroplasia, comprising the compound **P16**.

30 23. Use of a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively

charged, for the preparation of a pharmaceutical composition for inhibiting growth factor receptor tyrosine kinase activity.

24. The use according to claim 23, wherein said growth factor receptor tyrosine kinase is selected from fibroblast growth factor (FGF) receptor tyrosine kinase, epidermal growth factor (EGF) receptor tyrosine kinase, platelet derived growth factor (PDGF) receptor tyrosine kinase, vascular endothelial growth factor (VEGF) receptor tyrosine kinase, nerve growth factor (VGF) receptor tyrosine kinase, hepatocyte growth factor (HGF) receptor tyrosine kinase, insulin receptor tyrosine kinase and insulin-like growth factor (IGF) receptor tyrosine kinase.

25. The use according to claim 24 for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity.

26. The use according to claim 25 for inhibition of angiogenesis.

27. The use according to claim 25 for inhibition of vascular smooth muscle cell proliferation in disorders including atherosclerosis, hyperthrophic heart failure and postsurgical restenosis.

28. The use according to claim 25 or 26, for inhibition of cell proliferation and migration in the treatment of primary tumors and metastasis.

29. The use according to claim 25 for treatment of nonmalignant tumors such as benign prostate hyperthrophy.

30. The use according to claim 25 for treatment of diabetic retinopathy.


31. The use according to claim 25 for treatment of psoriasis.

32. The use according to claim 25 for treatment of rheumatoid arthritis.

33. The use according to claim 25 for treatment of disorders including retrolental fibroplasia, macular degeneration, hemangioma, arteriovenous malformation, hypertrophic scars, scleroderma and autoimmune diseases.


34. The use according to claim 24 for the treatment of bone and cartilage related disorders including inherited skeletal disorders e.g. achondroplasia, dwarfism, craniosynostosis.

35. The use according to any one of claims 23-34 wherein the 5,10,15,20-tetraaryl-porphyrin has the formula:



10 wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion.

15 36. The use according to any one of claims 23-34 wherein the 5,10,15,20-triarylcorrole has the formula:



25 wherein Ar_1 , Ar_2 , and Ar_3 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 3 and X is a pharmaceutically acceptable anion.

30 37. The use according to claim 35 or 36, wherein said carboaryl radical by itself or as part of the mixed carboaryl-heteroaryl radical is a substituted monocyclic or bicyclic aromatic radical and said heteroaryl radical is a substituted 5-6 membered aromatic ring containing 1-3 heteroatoms selected from O, S and/or N.

38. The use according to claim 37, wherein said carboaryl radical is selected from phenyl, biphenyl and naphthyl substituted by one or more halogen atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

5 39. The use according to claim 38, wherein said carboaryl radical is phenyl substituted by fluoro and optionally by tri-(C₁-C₈)alkylammonium or amino-(C₁-C₈alkyl) amino.

40. The use according to claim 39, wherein one or two of said carboaryl radicals is pentafluorophenyl and/or 4-aminopropylamino-2,3,5,6-pentafluorophenyl.

10 41. The use according to claim 39, wherein one to four of said carboaryl radicals is 4-trimethylammoniophenyl or 4-trimethylammonio- 2,3,5,6-pentafluorophenyl.

42. The use according to claim 37, wherein said heteroaryl radical by itself or as part of a mixed carboaryl-heteroaryl radical is selected from furyl, thienyl, pyrrolyl, imidazolyl, thiazolyl, pyridyl, pyrimidyl, triazinyl substituted by one or more halogen
15 atoms, and/or one or more C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylamino, amino-(C₁-C₈) alkylamino, and tri-(C₁-C₈) alkylammonium radicals.

43. The use according to claim 42, wherein said one to four of said heteroaryl radicals is N-(C₁-C₈alkyl)-pyridylum.

44. The use according to claim 43, wherein said radical is selected from 2-, 3- or
20 4-(N-methyl) pyridylum.


45. The use according to claim 35 or 36, wherein said mixed carboaryl-heteroaryl radical is 4-(N-methyl-2-pyridylum)-2,3,5,6-tetrafluoro-phenyl.

46. The use according to any one of claims 23-35, wherein said porphyrin compound is selected from one of the compounds herein designated **P1**, **P5**, **P6**, **P7**, **P8**, **P9**, **P10**,
25 **P15**, **P16**, **P17**, **P18**, **P19** and **P20**.

47. The use according to any one of claims 23-34 and 36, wherein said corrole compound is the compound herein designated **P21**.

48. A 5,10,15,20-tetraaryl-porphyrin of the formula:

5



- 10 wherein Ar_1 , Ar_2 , Ar_3 , and Ar_4 , the same or different, are each an aryl radical selected from a carboaryl, a heteroaryl and a mixed carboaryl-heteroaryl radical, at least two of said aryl radicals being positively charged, n is an integer from 2 to 4 and X is a pharmaceutically acceptable anion, and wherein at least one of the non-positively charged aryl radicals, if present, is pentafluorophenyl or
- 15 4-amino(C_1 - C_8)alkylamino-2,3,5,6-tetrafluorophenyl, and at least two of the positively charged aryl radicals are N -(C_1 - C_8)alkyl-pyridylium or 4-(N - C_1 - C_8 alkyl-pyridylium)-2,3,5,6-tetrafluoro-phenyl.

49. The porphyrin of claim 48 being selected from one of the compounds herein designated **P16**, **P17**, **P18**, **P19** and **P20**.

- 20 50. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a tetrapyrrolic macrocycle selected from a 5,10,15,20-tetraaryl-porphyrin according to claim 48 and a 5,10,15-triaryl-corrole, wherein said aryl radical of the corrole compound is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged.

- 25 51. A pharmaceutical composition according to claim 50 wherein the 5,10,15,20-tetraaryl-porphyrin according to claim 48 is one of the compounds herein designated **P16**, **P17**, **P18**, **P19** and **P20**.

52. A pharmaceutical composition according to claim 50 wherein the 5,10,15-triaryl-corrole is a corrole as defined in any one of claims 7-16.

- 30 53. The pharmaceutical composition according to claim 52 wherein the 5,10,15-triaryl-corrole is the compound herein designated **P21**.

54. A method for inhibiting growth factor receptor tyrosine kinase activity comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit growth factor receptor activity.




55. A method for inhibiting angiogenesis comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit angiogenesis.

56. A method for prevention of restenosis after percutaneous transluminal coronary angioplasty comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit smooth muscle cell proliferation.

57. A method for inhibiting primary tumor growth and metastasis comprising the administration of an inhibitor selected from a tetrapyrrolic macrocycle selected from 5,10,15,20-tetraaryl-porphyrin and 5,10,15-triaryl-corrole, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, in an amount sufficient to inhibit primary tumor growth and metastasis.

ABSTRACT

Tertrapyrrolic macrocycles selected from 5, 10, 15, 20-tetraaryl-porphyrins and 5, 10, 15-triaryl-corroles, wherein said aryl radical is a carboaryl, a heteroaryl or a mixed carboaryl-heteroaryl radical and at least two of said aryl radicals are positively charged, inhibit growth factor (e.g. bFGF, VEGF) receptor tyrosine kinase activity, and are useful for inhibition of cell proliferation mediated by growth factor receptor tyrosine kinase activity for example for inhibition of angiogenesis, or vascular smooth muscle cell proliferation in disorders including atherosclerosis, hypertrophic heart failure and postsurgical restenosis, and of cell proliferation and migration in the treatment of primary tumors and metastasis. Some of the 5, 10, 15, 20-tetraaryl-porphyrins are novel compounds.



2/16

Inhibitor	FGFR1		FGFR3	
	+bFGF		+FGF9	
	+	-	+	-
203 →		■		■
117 →				

Fig. 2




Fig. 3

3/16




Fig. 4

4/16




Fig. 5

5/16




Fig. 6

6/16




Fig. 7

7/16




Fig. 8A

8/16




Fig. 8B

9/16




Fig. 9

10/16




Fig. 10A

11/16




Fig. 10B

12/16




Fig. 11

13/16




Fig. 12

14/16




Fig. 13

15/16

Fig. 14




Fig. 15A





Fig. 15B



16/16




Fig. 16

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appln. No. _____*; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/_____; filed _____ entry requested on _____*; national stage application received U.S. Appln. No. _____*; §371/§102(e) date _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent or inventor's certificate, or §365(a) of any prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked, and have also identified below, by checking the "No" box, any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application on which priority is claimed:

<u>126953</u>	<u>Israel</u>	<u>08 November 1998</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)
<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
624 Ninth Street, N.W.
Washington, D.C. 20001-5303
(202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from Webb, Ben-Ami & Associates as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

Combined Declaration for Patent Application and Power of Attorney

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES

the specification of which (check one)

- ☐ is attached hereto;
☐ was filed in the United States under 35 U.S.C. §111 on _____, as U.S. Appl. No. _____*; or
☒ was/will be filed in the U.S. under 35 U.S.C. §371 by entry into the U.S. national stage of an international (PCT) application, PCT/_____; filed _____, entry requested on _____*; national stage application received U.S. Appl. No. _____*; §371/§102(c) date _____* (* if known)

and was amended on _____ (if applicable).

(include dates of amendments under PCT Art. 19 and 34 if PCT)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119 (a)-(d) and 365 (b) of any prior foreign application(s) for patent or inventor's certificate, or §365(a) of any prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked, and have also identified below, by checking the "No" box, any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application on which priority is claimed:

<u>126953</u>	<u>Israel</u>	<u>08 November 1998</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional applications listed below:

<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)
<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any prior U.S. non-provisional application(s) or under §365(c) of any prior PCT international application(s) designating the U.S., listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT international application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information which is material to patentability as defined in 37 C.F.R. §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
<u> </u>	<u> </u>	<u> </u>
(Application No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

As a named inventor, I hereby appoint the following registered practitioners to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

All of the practitioners associated with Customer Number 001444

Direct all correspondence to the address associated with Customer Number 001444, which is presently:

BROWDY AND NEIMARK, P.L.L.C.
 624 Ninth Street, N.W.
 Washington, D.C. 20001-5303
 (202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents appointed herein to accept and follow instructions from Webb, Ben-Ami & Associates as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents appointed herein will be so notified by the undersigned.

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES

U.S. Application filed

Serial No.

PCT Application filed 08 November 1999

Serial No. PCT/IL99/00602

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR Avner YAYON	INVENTOR'S SIGNATURE	DATE
RESIDENCE Meshek 104, Moshav Sitria 73272, Israel	CITIZENSHIP IL	
POST OFFICE ADDRESS Meshek 104, Moshav Sitria 73272, Israel		
FULL NAME OF SECOND JOINT INVENTOR David AVIEZER	INVENTOR'S SIGNATURE	DATE
RESIDENCE Hateena Street 4, Hashmonaim 73127, Israel	CITIZENSHIP IL	
POST OFFICE ADDRESS Hateena Street 4, Hashmonaim 73127, Israel		
FULL NAME OF THIRD JOINT INVENTOR Zeev GROSS	INVENTOR'S SIGNATURE <i>Zeev Gross</i>	DATE 10.6.01
RESIDENCE Hibner Street 1, Petach Tikva 49400, Israel	CITIZENSHIP IL	
POST OFFICE ADDRESS Hibner Street 1, Petach Tikva 49400, Israel		
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SEVENTH JOINT INVENTOR	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING PORPHYRINS AND SOME NOVEL PORPHYRIN DERIVATIVES

U.S. Application filed _____, Serial No. _____
 PCT Application filed 08 November 1999 Serial No. PCT/IL99/00602

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR Avner YAYON		INVENTOR'S SIGNATURE <i>Avner Yayon</i>	DATE May 16, 2001
RESIDENCE Meshek 104, Moshav-Sitria 73272, Israel <i>IL</i>		CITIZENSHIP IL	
POST OFFICE ADDRESS Meshek 104, Moshav Sitria 73272, Israel			
FULL NAME OF SECOND JOINT INVENTOR David AVIEZER		INVENTOR'S SIGNATURE <i>David Aviezer</i>	DATE May 16, 2001
RESIDENCE Hateena Street 4, Hashmonaim 73127, Israel <i>IL</i>		CITIZENSHIP IL	
POST OFFICE ADDRESS Hateena Street 4, Hashmonaim 73127, Israel			
FULL NAME OF THIRD JOINT INVENTOR Zeev GROSS		INVENTOR'S SIGNATURE <i>Zeev Gross</i>	DATE
RESIDENCE Hibner Street 1, Petach Tikva 49400, Israel <i>IL</i>		CITIZENSHIP IL	
POST OFFICE ADDRESS Hibner Street 1, Petach Tikva 49400, Israel			
FULL NAME OF FOURTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SIXTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR		INVENTOR'S SIGNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			